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Time trends in incidence and mortality of respiratory diseases of 
high public health relevance in Germany
Abstract
Respiratory diseases are major causes of disease burden and mortality throughout the world. In Germany, alongside 
acute respiratory infections (ARI), chronic lung diseases – including lung cancer, chronic obstructive pulmonary 
disease (COPD), and asthma – are of particular socioeconomic importance. ARI incidence rates differ significantly 
according to age, season and year. They are recorded as weekly consultation rates as reported by selected outpatient 
and inpatient care facilities. Between 2009 and 2016, the highest incidence rates of severe acute respiratory infection 
(SARI) were recorded among young children in outpatient (9.4%) and inpatient (0.2%) care. Mortality rates for ARI 
are also subject to seasonal and annual fluctuations. However, the official statistics on causes of death, which lead 
to estimates of more than 17,000 annual deaths, provide an inadequate measure of death rates because chronic 
underlying illnesses are often recorded as the cause of death rather than a more recently acquired acute infection. 
Therefore, the excess mortality caused by ARI needs to be assessed in the context of influenza outbreaks. Regarding 
lung cancer, COPD and asthma, the long-term time trends in disease incidence and mortality rates are of particular 
interest from a health policy perspective. Analyses of data from the official statistics on causes of death for the years 
1998 through 2015 show that mortality rates for lung cancer and COPD decreased on average by 1.8% and 1.1% per 
year respectively, among men, whereas among women they increased by 2.5% (lung cancer) and 2.3% (COPD) 
annually. Nevertheless, more men than women died of lung cancer or COPD in 2015 in Germany: 29,378 men and 
15,881 women died from lung cancer, and 17,300 men and 13,773 women died from COPD. During the same period, 
the asthma mortality rates decreased on average by 8.3% annually among women and by 11.2% annually among 
men, and the absolute number of deaths came down to 659 among women and 393 among men. Lung cancer 
incidence rates have been at similar levels as lung cancer death rates since 1998. No such data are available on 
time trends in COPD or asthma incidence rates. Coordinated surveillance of respiratory diseases needs to be 
expanded within the framework of international action plans for disease prevention.
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ified J18) among men, count among the ten most fre-
quent causes of death in Germany [8]. The importance 
of these diseases is also reflected by the impact on the 
health care system. Every year, seasonal influenza is a 
major cause of extra visits in ambulatory care [14]. 
Depending on the season, influenza can cause up to 
30,000 hospitalisations due to complications of primary 
influenza and secondary bacterial infection [14]. The 
number of pulmonary infections that occur outside of 
hospital (community-acquired pneumonia) is estimated 
at between 400,000 and 600,000. Approximately 30% 
to 50% of these cases lead to hospitalisation [15, 16]; 
community-acquired pneumonia should be treated in 
accordance with the S3 guideline [17]. Nevertheless, 
pneumonia is often the result of hospital-acquired (noso-
comial) infections. According to a study of the burden 
of disease associated with nosocomial infections in 
Europe, the incidence of nosocomial pneumonia (health-
care-associated pneumonia – HAP) is 138 per 100,000 
population [18]. Calculated in DALYs (disability-adjusted 
life years), which is an internationally established stan-
dard for measuring the burden of disease caused by an 
illness or pathogen, HAP (with a rate of 169 per 100,000 
individuals) is the most important disease in terms of 
severity and case fatality among the six frequently occur-
ring nosocomial infections examined in this study. How-
ever, only data from hospitals were taken into account 
in this case – data from nursing homes were not included 
[18]. In addition, COPD and asthma are not only com-
mon causes of outpatient care visits [19]. As chronic 
conditions that can be treated in an ambulatory care 
setting, both diseases are among the major causes of 
1. Introduction
In Germany and throughout the world, diseases of the 
airways and lung are of significant socioeconomic impor-
tance [1-7]. Within the current framework of the interna-
tional system of disease classification (10th revision of 
the International Statistical Classification of Diseases 
and Related Health Problems, ICD-10), this group of 
diseases not only covers a wide range of acute and chron-
ic disorders of the respiratory system (J00-J99), but also 
malignant neoplasms (cancer) of the trachea, bronchus 
and lung (C33-C34) [2]. Recent data from Germany (2015) 
show that 12.3% of all deaths are caused by respiratory 
diseases (ICD-10: J00-J99 including C33-C34) [8]. The 
direct costs incurred from the treatment of respiratory 
disorders alone (including C33-C34) amount to EUR 14.7 
billion (2008) [2]. Respiratory system disorders – along-
side musculoskeletal disorders and connective tissue 
diseases – were the most common reason that patients 
sought treatment in a doctor’s practice in 2016 [9]. They 
are also among the most important factors that cause 
people to take time off work [2, 10]. In Germany, along-
side acute diseases of the respiratory tract (J00-J22), lung 
cancer (C33-C34), chronic obstructive pulmonary disease 
(COPD, J44), and asthma (J45-J46), in particular, are 
associated with a high burden of disease and mortality 
[1-7, 11, 12]. They are, therefore, of particular relevance 
to public health and are also the central focus of the 
World Health Organization’s (WHO) surveillance and 
prevention strategies [1, 11-13].
Lung cancer (C33-C34) and COPD (J44) among both 
genders, and pneumonia (pneumonia, organism unspec-
The incidence rate of acute 
respiratory infections is 
highly dependent on age and 
fluctuates strongly according 
to the time of year and the 
severity of the influenza 
season. 
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national level to describe time trends in the incidence 
and mortality due to acute respiratory infections and 
chronic lung diseases of high relevance to public health.
2. Methods
The current investigation relies on data sources avail-
able at the national level to analyse time trends in inci-
dence (Info boxes 1 and 2) and mortality rates (Info box-
es 3 and 4) of acute respiratory infections (ARI), lung 
cancer, COPD and asthma. It includes data on ARI from 
primary care practices and hospitals (syndromic surveil-
lance), [26, 27] from the RKI’s Centre for Cancer Registry 
Data (ZfKD) [28, 29], and from the official statistics on 
causes of death [8] (Info boxes 3, 5, 6 and 7). In addition, 
the incidence rate of asthma among adults during the 
observation period between 1997-1999 and 2008-2011 
was estimated based on data from the nationwide inter-
view and examination surveys regularly conducted by 
the RKI as part of the German Federal Health Monitor-
ing system [30-33] (Info box 8).
2.1 Acute respiratory infection (ARI)
Case definition
In primary care practices, an acute respiratory infection 
(ARI) was counted if a doctor diagnosed a disease by 
entering at least one of the following ICD-10 codes into 
the medical information system: J00-J22 (J00-J06: acute 
upper respiratory infections; J09-J18: influenza and pneu-
monia; J20-J22: other acute lower respiratory infections) 
or an individual diagnosis of J44.0 (chronic obstructive 
potentially avoidable hospital admissions with more than 
270,000 hospitalisations in 2015 [20-23]. Around 190,000 
cases of lung cancer were treated in hospitals in 2015, 
which provides an illustration of the considerable level 
of medical care associated with this disease [23, 24].
Continuous and timely disease monitoring including 
incidence and mortality rates is indispensable in infec-
tion control and also forms the basis of the WHO’s 
Global Action Plan for the Prevention and Control of 
NCDs 2013-2020 [12, 13]. At the Robert Koch Institute 
(RKI), assessments of the rates of new cases and deaths 
(incidence and mortality, see Info box 1, 2, 3 and 4) asso-
ciated with acute respiratory infections (ARI) and cancer, 
including lung cancer, are carried out continuously as 
part of the ongoing surveillance of infectious diseases 
and the pooled analyses of federal state-level epidemi-
ological cancer registry data held by the German Centre 
for Cancer Registry Data (ZfKD). In addition, data on the 
epidemiology of respiratory diseases are available from 
the population-based, representative health surveys car-
ried out at regular intervals by the RKI and from the offi-
cial statistics on causes of death published by the Fed-
eral Statistical Office (Info box 3). All these data are 
integrated into the German Federal Health Monitoring 
information system [25]. Additional information on the 
prevalence (Info box 1) of lung cancer is published at 
regular intervals by the ZfKD [24]. Two Fact sheets pub-
lished in this issue use data from the German Health 
Update (GEDA 2014/2015-EHIS) nationally health inter-
view survey to provide current assessments of the preva- 
lence of known COPD and asthma among adults. The 
current analyses are based on data available at the 
Info box 1:  Measures of disease  
frequency 
Prevalence: The prevalence is the frequency of a cer-
tain disease within a defined population in a specific 
period of time. It is usually expressed as the per-
centage of the people who have had a certain dis-
ease, e.g., within the last 12 months (12-month preva- 
lence) or during their life (lifetime prevalence).
 
Incidence: The incidence is the frequency of new cas-
es of a certain disease within a defined population 
in a specific period of time. It is often expressed as 
a percentage of new cases within a specific period 
(cumulative incidence) or as the number of new 
cases per 1,000 person-years (incidence rate). 
Cumulative incidence: The number of new cases is 
divided by the original number of people at risk. In 
other words, this is the proportion of a population 
that could develop the disease in a defined period of 
time (for example, at the beginning of a twelve-year 
study period). In order to calculate the cumulative 
incidence of a certain disease, new cases are count-
ed only among people who did not have the disease 
at the start of the study (Annex Table 3).
Incidence rate: The incidence rate is the number of 
new cases divided by the so-called person-time at 
risk. The person-time at risk corresponds to the du-
ration of time during which the people in a defined 
population are at risk of developing a disease. It can 
vary from person to person. For example, not every-
one is at risk of developing a certain disease for the 
entire study duration because they may develop the 
disease before the study ends (Annex Table 3) [41]. 
According to international standards for cancer reg-
istration, the annual incidence rate of lung cancer is 
calculated as the proportion of the average total
Continued on next page
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resulting from influenza, as influenza viruses can cause 
acute respiratory diseases, and unlike many viruses caus-
ing the common cold, can account for serious illnesses 
and death. The RKI’s Working Group Influenza (Arbeits-
gemeinschaft Influenza, AGI) has provided data on out-
patient care for many years (see Info box 5). Moreover, 
an ICD-10-code based, electronic reporting system was 
included in the syndromic routine surveillance since 
2012/2013. This includes keeping electronic records of 
diagnostic codes [26]. The weekly ARI consultation rate 
(see Info box 2) is an important indicator for ARI activi-
ty. Due to its strong association with age, the consulta-
tion rate is estimated in five age groups separately [27]. 
For severe acute respiratory infections (SARI), the RKI 
has also developed a continuous syndromic sentinel 
pulmonary disease with acute lower respiratory infec-
tion) or B34.9 (viral infection, unspecified). In order to 
assess the burden of severe acute respiratory infections 
(SARI) in inpatient care, cases with a discharge diagno-
sis of influenza, pneumonia or other acute lower respira-
tory infection (ICD-10 J09-J22, Table 1) were selected.
Incidence of acute respiratory infection (ARI)
A syndrome is a typical combination of several symp-
toms or diagnoses (or, in this case, the ICD-10 codes 
used to describe them) associated with a particular dis-
ease. The RKI conducts syndromic surveillance of acute 
respiratory infection (ARI) in both outpatient (general 
practitioners and paediatricians) and inpatient (hospi-
tal) care. It is particularly used to monitor the conditions 
Info box 1 (continued)
population of the respective reference year that de-
velops lung cancer in that year [24]. The number of 
people with previously diagnosed lung cancer 
among the total population is considered negligi-
ble. Thus, the average total population of the re-
spective reference year is simplified and equated 
with the number of people at risk for that year. The 
incidence rate is presented as the number of new 
cases of lung cancer per 100,000 population. 
Source: [24, 41, 129]
Table 1 
Mortality due to respiratory diseases 
including lung cancer in 2015, Germany 
(≥0 years of age) by gender 
Data source: Official statistics on 
causes of death [8]
ICD-10 codes Gender Number of 
deaths
Deaths per 100 thousand 
population (crude rate) 
J00-J99 Diseases of the respiratory system Women 31,700 76.4
Men 36,600 91.1
J09-J22 Severe acute respiratory infections (SARI)1 Women 10,743 25.9
Men 10,816 26.9




J44 Chronic obstructive pulmonary disease Women 13,773 33.2
(COPD) Men 17,300 43.1
J45-J46 Asthma Women 659 1.6
Men 393 1.0
C33-C34 Malignant neoplasms of the trachea, 
bronchus and lung 
Women 15,881 38.3
Men 29,378 73.1
C34 Malignant neoplasms of bronchus and lung Women 15,870 38.2
Men 29,354 73.1
1  Severe acute respiratory infections (SARI): influenza, pneumonia and other acute infections of the lower respiratory tract.
ICD-10=10th revision of the International Statistical Classification of Diseases and Related Health Problems
6
Journal of Health Monitoring Time trends in incidence and mortality of respiratory diseases of high public health relevance in Germany FOCUS
Journal of Health Monitoring 2017 2(3)
nocarcinomas (8140-8384), squamous cell carcinomas 
(8050-8080), unspecified lung tumours (8000-8005), 
and other malignant lung carcinomas (8010-8011) 
(Annex Figure 1).
Incidence of lung cancer
The analyses of lung cancer incidence rates are based 
on data from the epidemiological cancer registries of 
the federal states, which transmit data annually to the 
German Centre for Cancer Registry Data (ZfKD) in 
accordance with the Federal Cancer Registry Data Act 
(Info box 7). The nationwide incidence of lung cancer 
(Info box 1) was calculated using this data [29]. Trends 
in lung cancer incidence rates were examined for the 
years 1998 through 2013 (see 2.5).
Mortality of lung cancer
Age and gender-specific mortality rates for lung cancer 
are based on data from the official statistics on causes 
of death provided by the Federal Statistical Office (Info 
box 3 and 4). Trends in lung cancer mortality rates were 
examined for the years 1998 through 2015 (see 2.5).
2.3 Chronic obstructive pulmonary disease (COPD)
Case definition
The case definition of deaths from COPD was based on 
the ICD-10 code (Info box 3) J44 for other chronic 
obstructive pulmonary disease [2] (Table 1). In order to 
ensure comparability with previous analyses of COPD 
mortality, ICD-10 codes for COPD and other chronic low-
er respiratory diseases (ICD-10: J40-J44, J47) were con-
surveillance system in hospitals (the ICOSARI project) 
within a scientific cooperation with the HELIOS Kliniken 
GmbH (see Info box 6). An important indicator in this 
regard is the weekly SARI hospitalisation rate (see Info 
box 2). Just as the ARI consultation rate, these estimates 
are also reported stratified by five age groups (0-4, 5-14, 
15-34, 35-59 and 60 years of age or older) [14 , 34].
Mortality of severe acute respiratory infections (SARI)
Age and gender-specific mortality rates for severe acute 
respiratory infections are based on data from the official 
statistics on causes of death provided by the Federal Sta-
tistical Office (Info box 3 and 4). Trends in mortality rates 
for severe acute respiratory infections were examined 
for the years 1998 through 2015 (see 2.5).
2.2 Lung cancer
Case definition
The definition of incident cases and deaths from lung 
cancer was made in accordance with the current inter-
national classification of diseases (10th revision of the 
International Statistical Classification of Diseases and 
Related Health Problems, ICD-10) and is based on the 
following ICD-10 codes: C33 for very rare malignant neo-
plasms of the trachea, and C34 for malignant neoplasms 
of the bronchus and lung (Table 1). In order to differen-
tiate among the different types of lung cancer, the mor-
phology codes recorded in the cancer registries were 
classified as follows (in accordance with the current 
International Classification of Diseases for Oncology – 
ICD-O-3): small cell lung carcinomas (8041-8045), ade-
Info box 2:  The consultation and 
hospitalisation incidence 
The consultation incidence of acute respiratory infec-
tion (ARI):
Visits to a doctor because of a medical condition in 
order to gain medical advice (and treatment) can 
also be called a consultation. The ARI consultation 
incidence refers to the number of people per 100,000 
population who have visited (consulted) a general or 
paediatric practice due to a new acute respiratory in-
fection in a given week. If the weekly ARI consultation 
incidence is assessed by age groups, the values are 
based on 100,000 population of the respective age 
group. Doing so demonstrates that children aged 4 
years or below have the highest risk of developing a 
medically attended ARI. This indicator can also be 
expressed as a percentage (as a proportion of 100 
population), resulting in a weekly ARI rate.
The hospitalisation incidence of severe acute respiratory 
infection (SARI):
If someone is treated for an acute respiratory infec-
tion in hospital, it can be termed that he or she was 
hospitalised due to the infection in question. The 
SARI hospitalisation incidence is the number of 
people per 100,000 population who have been hos-
pitalised due to a severe acute respiratory infection 
(SARI) in a given week. If the weekly SARI hospitali-
sation incidence is assessed by age groups, the val-
ues are based on 100,000 population from the re-
spective age group. Doing so demonstrates that 
children aged 4 years or below and elderly people 
aged 60 years or above have a higher risk of being 
treated in a hospital for severe respiratory infections 
than children older than 4 years of age or adults be-
low the age of 60 years. This indicator can also be 
expressed as a percentage (as a proportion of 100 
population), resulting in a weekly SARI rate.
Source: [27]
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from 3,959 participants of the DEGS1 study who partic-
ipated in both the baseline survey (GNHIES98, 1997-
1999) and the follow-up survey (DEGS1, 2008-2011) (see 
Info box 8). Participants (n=290) were excluded from 
the analyses because they reported to have ever been 
diagnosed with asthma by a physician at the time of the 
baseline survey (1997-1999) or because complete infor-
mation about their asthma status was unavailable at 
baseline and/or follow-up survey. All results were report-
ed by gender and further stratified by two age groups 
(18-44 and 45-79 years of age) (Table 4). Estimates on 
asthma incidence were calculated by using a specific 
weighting factor in order to correct not only for devia-
tions of the baseline sample from the population struc-
ture at the time of data collection, but also to adjust for 
selective participation at follow-up [38]. For comparabil-
ity with other studies, asthma incidence rates per 1,000 
person-years were also estimated (Info box 1). Due to 
varying degrees of disease activity over time in individ-
uals with asthma and resulting effects on self-reported 
information from those that are affected, different selec-
tion criteria of study participants for analyses on asthma 
incidence (population at risk, Info box 1) are found in 
the literature [39-42]. Therefore, incidence rates were 
additionally calculated after excluding specific partici-
pants who may have already had asthma before the base-
line survey was conducted (see Annex Table 3). 
Mortality of asthma
Age and gender-specific mortality rates for asthma are 
based on data from the official statistics on causes of death 
provided by the Federal Statistical Office (Info box 3 
sidered in combination; only the ICD-10 codes for asth-
ma (J45-J46) were excluded (Table 1) [35-37].
Mortality of COPD
Age and gender-specific mortality rates for COPD are 
based on data from the official statistics on causes of 
death provided by the Federal Statistical Office (Info box 
3 and 4). Trends in COPD mortality rates were examined 
for the years 1998 through 2015 (see 2.5).
2.4 Asthma
Case definition
Based on data from the national health interview and 
examination surveys, incident cases of asthma (Info box 
8) were defined as those participants who reported to 
have ever been diagnosed with asthma by a physician 
and having had asthma and/or having used asthma med-
ication in the past 12 months. The case definition of 
death from asthma was based on the asthma-specific 
ICD-10 codes (Info box 3) J45-J46 [2] (Table 1).
Incidence of asthma among adults
The current analysis is based on data from the German 
Health Interview and Examination Survey for Adults 
(DEGS1) conducted by the RKI as part of the continuous 
health monitoring system in Germany [30-33]. DEGS1 
has a mixed study design which allows for both cross-sec-
tional and longitudinal analyses [30-32]. The study’s con-
cept and design is described in detail elsewhere [30-32]. 
Gender-specific estimates of the cumulative incidence 
of asthma (Info box 1) were calculated based on data 
Info box 3:  Causes of death 
Causes of death: The official statistics on causes of 
death provide information about the most impor-
tant causes of death and trends in death rates. From 
1 January 1998 onwards, the 10th revision of the In-
ternational Statistical Classification of Diseases and 
Related Health Problems (ICD-10) has been in use 
to code the causes of death that occurred during the 
observation period. The statistics on causes of death 
are derived from an evaluation of death certificates. 
These are issued individually on the basis of the fed-
eral states’ burial laws for all deaths as well as for 
stillborns with a birth weight of at least 500g and are 
pooled at the Federal Statistical Office.
Source: [129]
The mortality rate for severe 
acute respiratory infections is 
not recorded adequately by 
statistics on causes of death; 
therefore, additional esti-
mates need to be made of the 
excess mortality associated 
with influenza outbreaks.
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indicate, for example, points at which incidence rates 
begin increasing more noticeably or level out [44]. In 
order to account for the impact of changes to the pop-
ulation age structure, the rates were standardised accord-
ing to age using the old European standard population 
(Info box 9). In addition, time trends in mortality rates 
for asthma and COPD were compared to time trends in 
mortality rates for all causes [37, 45]. For all outcomes 
of interest, the number of absolute cases as well as the 
number of cases per 100,000 population were present-
ed by calendar year. Population estimates reflect the 
average total population of the respective reference year. 
For the years 1998 through 2010, these figures were 
based on projections of census data collected in the for-
mer FRG in 1987 and in the former GDR in 1990 [8]. From 
2011 onwards, projections obtained from the 2011 cen-
sus were used [8]. All results were reported by gender 
and 4). Trends in asthma mortality rates were examined 
for the years 1998 through 2015 (see 2.5).
2.5 Analysis of time trends
The Joinpoint Regression Program (version 4.4.0.0, [43]) 
was used to analyse time trends in incidence and mor-
tality rates per 100,000 population. The average annual 
percentage change (AAPC) in the age-standardised rates 
(Info box 9) at the national level was estimated by per-
forming joinpoint regression analyses [43, 44]. Trends 
in the incidence rates for lung cancer were examined for 
the years 1998 through 2013, whereas trends in mortal-
ity rates for each included respiratory disease were exam-
ined for the years 1998 through 2015. In each analysis, 
years (‘joinpoints’) were identified, in which statistically 
significant changes in trends occurred. Such joinpoints 
Info box 4: Mortality 
Mortality: Mortality is the frequency of deaths within 
a given population during a specific period of time. 
It is usually expressed as a percentage of deaths 
within a certain period (cumulative mortality) or as 
the number of deaths per 1,000 person-years (mor-
tality rate). 
Cause-specific mortality rate: The cause-specific mor-
tality rate is based on the annual number of deaths 
attributed to a specific underlying cause as recorded 
in the official statistics on causes of death (Info box 
3). The average total population of the respective ref-
erence year is considered as the number of people at 
risk. Therefore, the annual number of deaths, for ex-
ample, from lung cancer, is divided by the average 
total population of the respective reference year and 
is presented as the number of deaths from lung can-
cer per 100,000 population.
Source: [24, 129]
Table 2 
Trends in age-standardised mortality rates 
(deaths per 100,000 population) due to respira-
tory diseases of high public health relevance 
and for all causes of death between 1998 and 
2015, Germany (old European standard 
population; ≥0 years of age) by gender 
Data source: Official statistics on 
causes of death [8]
ICD-10 codes  Gender Period APC (95% CI) Period APC (95% CI) AAPC (95% CI)
J09-J22 (Severe acute respiratory 
infections – SARI)
Women 1998-2005 1.9 -1.4/5.2 2005-2015 -4.3 -6.2/-2.4 -1.8 -3.4/-0.2
Men 1998-2007 0.0 -1.9/1.9 2007-2015 -3.9 -5.9/-1.9 -1.9 -3.1/-0.6
C33-C34 (Malignant neoplasms of 
the trachea, bronchus 
and lung)
Women 1998-2015 2.5 2.4/2.6
Men 1998-2006 -2.3 -2.7/-2.0 2006-2015 -1.4 -1.7/-1.1 -1.8 -2.0/-1.6
J40-J44, J47 (COPD and other chron-
ic lower respiratory dis-
eases excluding asthma)
Women 1998-2015 2.3 1.8/2.9
Men 1998-2007 -2.7 -3.8/-1.5 2007-2015 0.8 -0.5/2.1 -1.1 -1.8/-0.3
J45-J46 (Asthma) Women 1998-2006 -10.3 -11.2/-9.3 2006-2015 -6.5 -7.7/-5.4 -8.3 -9.0/-7.6
Men 1998-2008 -13.7 -14.5/-12.9 2008-2015 -7.6 -9.9/-5.2 -11.2 -12.2/-10.3
A00-T98 (All causes of death) Women 1998-2015 -1.4 -1.6/-1.2
Men 1998-2008 -2.5 -2.9/-2.2 2008-2015 -0.8 -1.3/-0.2 -1.8 -2.1/-1.5
APC=annual percentage change, and 95% confidence interval (95% CI)
AAPC= average annual percentage change, and 95% confidence interval (95% CI) between 1998 and 2015
COPD=chronic obstructive pulmonary disease
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2012/2013 influenza season) visited a general or paedi-
atric practice due to an acute respiratory infection. Large 
differences between age groups were identified year-
round, whereas gender-specific differences hardly played 
a role (data not shown). Each week, between 1.5% and 
9.4% of children aged 0 to 4 years visited a paediatrician. 
By contrast, no more than 1.3% of people aged 60 years 
or older visited their general practitioner due to an acute 
respiratory complaint – even in winter during weeks with 
high levels of influenza activity.
Only a small proportion of acute respiratory infections 
is severe enough to result in hospital treatment. Hospi-
tal admission due to severe acute respiratory infection 
(SARI) is also highly dependent on age. The weekly inci-
dence of SARI (hospitalisation incidence, Info box 1) is 
highest among children aged 0 to 4 years. In the period 
of 2009 to 2016, it ranged from 0.001% to 0.19% depend-
ing on the season and level of influenza activity. Between 
0.01% and 0.06% of adults aged 60 years or older were 
admitted to a hospital each week. The risk of a serious 
illness increases with age and with the presence of other 
risk factors, such as chronic pre-existing illnesses.
In 2015, a severe acute respiratory infection (ICD-
10: J09-J22) was reported as the underlying cause of 
death (monocausal cause of death) for 10,743 women 
and 10,816 men in Germany (Table 1). The crude mor-
(see Tables 2 and 3) and further stratified by age groups 
(0 to 54, 55 to 74, and 75 years of age or older, see Annex 
Tables 1 and 2). In contrast to the other age-associated 
chronic respiratory diseases considered here, asthma 
occurs frequently among people of all ages and may 
overlap with a COPD from mid- to late adulthood [2, 24, 
46-50]. For international comparability, time trends in 
asthma mortality rates were thus additionally analysed 
for people aged 5 to 34 years [51].
3. Results
3.1 Acute respiratory infections
Figure 1 shows the weekly changes in the consultation 
incidence of acute respiratory infections that occurred 
between 2009 and 2016. Depending on the week and 
season, up to 2.6% of the population (at the peak of the 
ICD-10 codes Gender Period APC (95% CI) Period APC (95% CI) AAPC (95% CI)
C33-C34    (Malignant neoplasms of 
the  trachea, bronchus 
and lung)
Women 1998-2008 3.9 3.7/4.2 2008-2013 2.1 1.4/2.7 3.3 3.1/3.6
Men 1998-2005 -1.8 -2.1/-1.5 2005-2011 -0.8 -1.3/-0.3 -1.5 -1.9/-1.2
2011-2013 -2.7 -4.8/-0.5
APC=annual percentage change, and 95% confidence interval (95% CI)
AAPC=average annual percentage change, and 95% confidence interval (95% CI) between 1998 and 2013
Table 3 
Trends in age-standardised incidence and mor-
tality rates (per 100,000 population) for malig-
nant neoplasms of the trachea, bronchus and 
lung (ICD-10 C33-C34) between 1998 and 2013, 
Germany (old European standard population; 
≥0 years of age) by gender 
Data Source: German Centre for Cancer 
Registry Data [28, 29]
Long-term time trends in the 
incidence and mortality of 
chronic lung diseases, 
including lung cancer, are of 
particular interest from a 
health policy perspective.
Table 4 
Cumulative incidence of asthma among 
adults (18-79 years of age) 
Data source: German Health Interview and 
Examination Survey for Adults 1997-1999 and 
2008-2011 [30-32]
Gender Age group Cumulative incidence 
(95% CI)
Women Total (18-79 years) 4.1 (2.8-5.7)
18-44 years 3.6 (1.9-6.1)
45-79 years 4.7 (2.8-7.3)
Men Total (18-79 years) 1.6 (0.9-2.6)
18-44 years 1.9 (1.0-3.5)
45-79 years 1.2 (0.5-2.2)
CI=Confidence interval
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3.2 Lung cancer
18,810 women and 34,693 men in Germany were diag-
nosed with lung cancer (ICD-10: C33-C34) in 2013 (see 
Figure 5). The average age at diagnosis was around 69 
years. The crude incidence rate was substantially higher 
among men (87.9 per 100,000) than among women (45.7 
per 100,000) (data not shown) and increased with age 
particularly among men (Figure 4). The absolute number 
of cases increased since 1998 among women but remained 
relatively constant among men. Correspondingly, sex-spe-
cific differences were found in the time trends of age-stan-
dardised incidence rates (Figure 6). Whereas among men 
the lung cancer incidence rate decreased on average 
(AAPC) by 1.5% annually between 1998 and 2013, women 
tality rate was 25.9 per 100,000 among women, which 
is very similar to the rate found among men (26.9). 
However, mortality rates increased significantly with 
age for both genders (Figure 2). Between 1998 and 2015, 
age-standardised mortality rates due to severe acute 
respiratory infections significantly declined on average 
(AAPC) by 1.8% annually among women and by 1.9% 
annually among men (Figure 3, Table 2). Most recently, 
a similar annual drop in mortality rates (APC, from 
2005 onwards) of 4.3% among men and 3.9% among 
women (see Table 2) has been observed. The overall 
decrease in mortality due to severe acute respiratory 
infection is mainly attributable to a marked decline 
among elderly (≥75 years) women and men (Annex 
Table 1). 
Figure 1 
Trends in the incidence of acute respiratory 
infections (ARI, ICD10: J00-J22, J44.0, B34.9) 
based on the weekly consultation rates (per 
100,000 population) between 2009 and 2016, 
Germany (men and women) by age 
Data source: Syndromic surveillance of acute 
respiratory infections (ARI) by the AGI 
(the RKI’s working group on influenza) [26, 27]
Lung cancer incidence and 
mortality rates decreased 
among men and increased 
among women.
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In 2015, lung cancer was reported as the underlying 
cause of death among more men (29,378) than women 
(15,881) (Table 1). The average age at death from lung 
cancer was 71 years. The crude mortality rate of 73.1 per 
100,000 was considerably higher among men than 
among women (38.3 per 100,000) and substantially 
increased with age particularly among men (Figure 2). 
In a manner similar to the incidence, there has been a 
clear increase since 1998 in the absolute number of 
deaths among women, whereas deaths among men 
remained largely unchanged during the same period 
(Figure 3; Figure 5). Differences were also found 
between age-standardised death rates among women 
showed a contrasting trend with an average annual 
increase of 3.3% (Table 3). However, among women under 
55 years of age, a 1.4% annual drop in the incidence of lung 
cancer can be observed from 2007 onwards (Annex Table 
2). When lung cancer incidence among women is exam-
ined according to morphological type, a larger increase 
can be identified for adenocarcinomas compared to squa-
mous cell carcinomas and small cell carcinomas. Adeno-
carcinomas also appear to be increasing among men 
despite the overall trend towards decreasing lung cancer 
incidence rates. However, it is important to recognise that 
the incidence rate of tumours classified as ‘unspecified’ 
also decreased during this period (Annex Figure 1) [24].
Figure 2 
Age-specific mortality rates (deaths per 100,000 
population) due to respiratory diseases 
of high public health relevance in 2015, 
Germany (≥0 years of age) by age and gender 
Data source: Official statistics on 
































































severe acute respiratory infections  (J09-J22)
malignant neoplasms of the trachea, bronchus and lung (C33-C34)






















































Journal of Health Monitoring Time trends in incidence and mortality of respiratory diseases of high public health relevance in Germany FOCUS
Journal of Health Monitoring 2017 2(3)
Figure 3 
Trends in the annual number of deaths 
(above) and age-standardised mortality 
rates (deaths per 100,000 population, below) 
due to respiratory diseases of high public 
health relevance between 1998 and 2015, 
Germany (old European standard population; 
≥0 years of age) by gender 
Data source: Official statistics on 








































































































































































severe acute respiratory infections (J09-J22)
malignant neoplasms of the trachea, bronchus and lung (C33-C34)
chronic obstructive pulmonary disease and other chronic lower respiratory diseases excluding asthma (J40-J44, J47)
asthma (J45-J46)
COPD mortality rates 
decreased among men and 
increased among women, 
whereas asthma mortality 
rates substantially declined 
for both genders.
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3.3 COPD
In 2015, COPD (ICD-10: J44) was reported as the under-
lying cause of death among more men (17,300) than 
women (13,773) (Table 1). The crude death rate was sub-
stantially higher among men (43.1 per 100,000 popula-
tion) than among women (33.2 per 100,000 population) 
and strongly increased with age particularly among men. 
Similar results were also seen when ICD-10 codes of 
COPD and other chronic lower respiratory diseases 
excluding asthma were considered (ICD-10: J40-J44, J47) 
(Table 1, Figure 2). This combination of ICD-10 codes is 
used internationally to enable comparability of long-term 
trends in COPD mortality over time, and is therefore 
also used below (see 2.3).
and men (Figure 3; Figure 6). Among men, there was 
a significant overall average annual decline of 1.8% 
(Table 2). Through 2006, this reduction was somewhat 
more marked (2.3%) before levelling out at 1.4% there-
after. The decrease in lung cancer mortality rates from 
2007 onwards is more noticeable among younger men 
(<55 years old) compared to older men (≥55 years old) 
(Annex Table 1). Among women there was, by contrast, 
a significant increase in lung cancer mortality of 2.5% 
annually over the entire observation period. However, 
as with the incidence, a reduction in lung cancer mor-
tality of 2.8% per year was observed among younger 
women (<55 years old).
Figure 4 
 Age-specific incidence and mortality rates 
(per 100,000 population) for malignant neo-
plasms of the trachea, bronchus and lung 
(ICD-10 C33-C34) in 2013, Germany 
(≥0 years of age) by gender 
Data Sources: German Centre for Cancer 
Registry Data [28, 29] and Official statistics 
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Figure 3 shows that the absolute number of deaths 
in 1998 was considerably lower among both women and 
men than in 2015. However, time trends in age-stan-
dardised death rates differed between women and men 
(Figure 3 and Table 2). Among women, there was a sig-
nificant increase of 2.3% annually over the entire obser-
vation period (Table 2). At the same time, an average 
annual increase in COPD mortality rates was most 
noticeable among women aged 55 to 74 years (Annex 
Table 1). Among men, there was, by contrast, a signifi-
cant overall average decline (AAPC) in COPD mortality 
rates of 1.1% annually (Table 2). However, this decrease 
came to a halt in 2007. A continuous decrease in mor-
tality rates was only seen among men aged 75 years or 
older (Annex Table 1). Gender differences can also be 
observed when time trends in COPD mortality rates are 
compared to time trends in all-cause mortality (Table 2): 
between 1998 and 2015, a similar average decline in 
COPD and in all-cause mortality rates was observed 
among men (-1.1% and -1.8% annually). By contrast, time 
trends in COPD and all-cause mortality differed among 
women: COPD mortality rates rose by 2.3% annually as 
opposed to a significant decrease in all-cause mortality 
rates of 1.4% annually.
3.4 Asthma
During an average observation period of approximately 
12 years, the cumulative incidence (Info box 1) of asth-
ma was higher among women (4.1%) than among men 
(1.6%) (Table 4). This gender difference was observed 
both at a younger age (18 to 44 years) and among older 
Figure 5 
Trends in the annual number of incident 
cases and deaths, malignant neoplasms 
of the trachea, bronchus and lung 
(ICD-10 C33-C34) between 1998 and 2013, 
Germany (≥0 years of age) by gender 
Data Sources: German Centre for Cancer 
Registry Data [28, 29] and Official statistics 
on causes of death [8]
Figure 6 
Trends in age-standardised incidence and mor-
tality rates (per 100,000 population) for malig-
nant neoplasms of the trachea, bronchus and 
lung (ICD-10 C33-C34) between 1998 and 2013, 
Germany (old European standard population; 
≥0 years of age) by gender 
Data Sources: German Centre for Cancer 
Registry Data [28, 29] and Official statistics on 
causes of death [8]
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4. Discussion
4.1 Acute respiratory infection
Syndromic surveillance of acute respiratory infections 
with a focus on influenza is an internationally recognised 
and established practice [52]. Laboratory analyses are 
only conducted in a very small proportion of cases with 
an acute respiratory infection. Moreover, 75% of all 
patients who were treated in inpatient care for commu-
nity acquired pneumonia left hospital with a diagnosis 
of J18 (pneumonia, unspecified organism) [53]. As such, 
assessing the individual diagnoses of influenza (instead 
of the fixed diagnostic groups used in syndromic sur-
veillance) would probably provide an incomplete and 
distorted depiction of the situation. Nevertheless, the 
syndromic approach has a clear disadvantage: the bur-
den of disease caused by individual pathogens such as 
influenza can only be estimated using relatively complex 
statistical procedures, which, at least in some cases, 
need to be accompanied by representative microbiologi-
cal examinations [12, 54]. Influenza infections and sub-
sequent pneumonia can also occur in hospitals. Such 
nosocomial pneumonia is often caused by pathogens 
that are already found in the respiratory tract (‘commen-
sals’) which are normally harmless and only cause dis-
ease once the mucous membrane of the respiratory tract 
has been weakened, for example, due to an influenza 
infection [55].
The occurrence of acute respiratory infections is char-
acterised by strong seasonal fluctuations. As such, a 
close (weekly) assessment of consultation rates is as 
relevant to health policy as analyses of long-term trends. 
adults (45 to 79 years). To enable comparability with oth-
er studies, incidence rates were also calculated (Info box 
1). Depending on the criteria considered for the selec-
tion of study participants in the analyses, asthma inci-
dence rates ranged from 2.7 to 3.4 per 1,000 person-years 
among women and from 1.1 to 1.3 per 1,000 person-years 
among men (Annex Table 3).
Among women and men, asthma (ICD-10: J45-J46) was 
rarely documented as the underlying cause of death in 
2015 (Table 1). The crude asthma mortality rate was sim-
ilar in women (1.6 per 100,000 population) and men 
(1.0 per 100,000 population) and increased with age 
among both genders (Figure 2). Figure 3 shows that the 
number of deaths from asthma among women and men 
in 1998 was considerably higher than in 2015. Between 
1998 and 2015, there was a strong decline in age-stan-
dardised asthma mortality rates, which was even more 
pronounced among men than among women (AAPC: 
-11.2% vs. -8.3%; Table 2). An annual decline in asthma 
mortality rates of 6.8% among women and of 7.5% 
among men was also observed in the age group 5 to 34 
years (data not shown). Finally, among both genders, a 
much faster average annual decline in asthma mortality 
rates than in all-cause mortality rates was observed in 
all age groups (AAPC for women aged ≥0 years: -8.3% 
vs. -1.4%; AAPC for men aged ≥0 years: -11.2% vs. -1.8%; 
Table 2).
Info box 5:  Data from the syndromic 
surveillance of acute res-
piratory infection (ARI) 
by the Working Group 
Influenza (Arbeitsgemein- 
schaft Influenza, AGI)
Data holder: Robert Koch Institute
Aims: Providing timely year-round surveil-
lance data of acute respiratory infections 
(ARI) in primary care with a focus on influ-
enza activity. This includes weekly reporting 
of the surveillance results.
Method used to estimate consultation inci-
dence: Weekly number of cases with medi-
cally attended acute respiratory infection 
(ARI) in sentinel practices of RKI’s Working 
Group Influenza
Population: Total population that sought a 
consultation with a general practitioner or 
paediatrician
Participants: Approximately 700 primary care 
physicians that regularly report to the RKI
Coverage: The participating sentinel prac- 
tices provide medical care to about 1% of the 
total population
Study period: Cases identified between 
1 Jan 2009 and 31 Dec 2016 have been includ-
ed in the results presented here
Source: [26, 27]
More information in German is available at 
https://influenza.rki.de/Default.aspx
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ly higher than the background mortality, the difference 
between expected and observed mortality rates can be 
attributed to the disease. This is referred to as excess 
mortality and can be estimated using statistical meth-
ods [56]. In the case of severe influenza seasons, such 
as those that occurred in 2012/2013 and 2014/2015, an 
excess mortality of 26 per 100,000 has been identified 
[14, 57]. This corresponds to 20,700 and 21,300 influen-
za-related deaths during the respective periods. Clearly, 
only a fraction of influenza-related deaths are stated as 
such in the annual statistics on causes of death due to 
severe respiratory infections. However, many respiratory 
infections that occur during an influenza season – includ-
ing the majority of pneumonia cases – are not caused 
by influenza; this applies even more to respiratory-coded 
deaths that occurred outside the influenza season.
4.2 Lung cancer
In the case of lung cancer, continuous and nationwide 
estimates of incidence and mortality rates are made in 
accordance with the Federal Cancer Registry Data Act of 
2009. Consistent with developments in the incidence 
rates, age-standardised mortality rates of lung cancer 
have been declining for decades among men and are 
still rising substantially among women. Due to the poor 
prognosis associated with lung cancer (about half of 
patients die within one year of being diagnosed) [24], the 
trends in mortality reflect the trends in incidence.
As the majority of lung cancer in Germany can be 
attributed to smoking, the different temporal trends 
found among women and men can be traced to changes 
In general, acute respiratory illnesses during the winter 
are significantly more pronounced in both outpatient 
and inpatient care than during the summer months. 
Although efficient health care systems, such as the one 
in Germany, are designed with this in mind, seasonal 
influenza waves occur in various strengths. A particu-
larly severe wave of influenza can tax the resources of 
outpatient and inpatient care for a few weeks. Further-
more, medical staff can also be affected by these out-
breaks and may fall ill during periods that already require 
greater level of medical care. Finally, people with chronic 
diseases are at a higher risk during these periods, as an 
additional respiratory infection could lead to a severe or 
even fatal disease; this also increases the level of care 
needed during influenza outbreaks.
Even if respiratory infections contribute to or actually 
cause death, they are rarely recorded as the monocausal 
cause of death; instead, an underlying condition is usu-
ally documented in the statistics on causes of death. 
Therefore, mortality rates and absolute number of deaths 
due to severe acute respiratory infections are likely 
underestimated, despite the fact that the mortality rate 
for community acquired, hospital-treated pneumonia is 
already high (at approximately 13% depending on age) 
[53]. As such, it is an international standard practice to 
estimate the influenza-related deaths by utilising the 
total number of deaths by any cause (Info box 10). This 
method usually involves calculating a background mor-
tality rate – the all-cause mortality rate that would have 
been expected at the time of the influenza season if there 
had been no influenza virus circulation. If the total mor-
tality rate observed during the influenza season is marked- 
Info box 6:  Data from syndromic 
surveillance of inpatient 
cases of severe acute res-
piratory infections (ICO-
SARI)
Data holder: Robert Koch Institute
Aims: Providing reliable and up-to-date infor-
mation on serious acute respiratory infec-
tions (SARI), with the possibility of compar-
ing different seasons and corresponding 
data from other countries.
Method used to estimate hospitalisation inci-
dence: Weekly data on the number of patients 
with a main discharge diagnosis of SARI 
from one of the hospitals participating in the 
ICOSARI project (sentinel hospitals) 
Population: The population in the catchment 
area of the sentinel hospitals, with the pos-
sibility of extrapolation to the total popula-
tion in Germany
Participants: Sentinel hospitals belonging 
to HELIOS Kliniken GmbH (83 in 2014)
Coverage: In 2014, the participating sentinel 
hospitals in 13 out of 16 federal states pro-
vided care to about 6% of all hospital patients 
across Germany
Study period: Cases identified between 
1 Jan 2009 and 31 Dec 2016 have been includ-
ed in the results presented here
Source: [14, 34]
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Oceania [62]. The increase in the proportion of adeno-
carcinomas observed in Germany has also been observed 
in many other countries over the last few decades [63, 
64]. Compared to the other two main forms of lung can-
cer (squamous cell carcinoma and small cell lung carci-
noma), adenocarcinoma is less strongly associated with 
smoking and is the most common form of lung cancer 
in non-smokers [65]. In this respect, a growing influence 
of environmental risk factors, such as particulate air pol-
lution, which are especially associated with adenocarci-
nomas, could play a role. However, the evidence in this 
regard is still limited [66], and particulate matter pollu-
tion (measured as PM10 values) seems to have declined 
in Germany since the mid-1990s, even if the values rec-
ommended by the WHO are still frequently exceeded in 
urban areas [67]. Other possible explanations for the 
increase in adenocarcinomas could be changes in the 
levels of tobacco consumption, the composition of 
tobacco products, the depth of inhalation and the age at 
which people begin to smoke.
4.3 COPD
Consistent with results on lung cancer mortality, in 2015, 
COPD was recorded as the underlying cause of death 
among more men than women. However, due to differ-
ent time trends in COPD mortality between women and 
men a further narrowing of the gender gap in death rates 
for COPD can be observed as already reported in Germa-
ny and other European countries since 1994 [35]. As with 
lung cancer, smoking is the most important modifiable 
risk factor of COPD in Germany [48, 68]. The risk of devel-
in smoking habits that occurred towards the end of the 
20th century. Whereas the proportion of smokers 
decreased among men, it rose among women until about 
2000, although it never reached the same level as among 
men [58]. Women have now also begun reducing their 
tobacco consumption, and this will have a significant 
effect in the coming decades. The rate of new lung can-
cer cases among women below the age of 55 years has 
fallen by 1.4% per year since 2007, and the mortality rate 
in this age group has been decreasing by 2.8% per year 
since 2008. This trend has been observed in almost all 
Western industrialised countries. In fact, in the US and 
some Scandinavian countries, a reduction in lung can-
cer incidence and mortality has already been observed 
among women overall, although the peak rates in these 
countries were substantially higher than in Germany. 
There are clear regional differences in lung cancer mor-
tality within the EU, and this is particularly the case 
among men: rates in some Eastern European countries 
are approximately three to four times higher than, for 
example, in Finland or Sweden [24].
Passive smoking, radon gas, other forms of environ-
mental pollution (especially particulates) and exposure 
to asbestos can also increase the risk of lung cancer. 
Long-term exposure not only to particulates themselves 
[59] but also to the pollutants that they carry increases 
the likelihood of lung cancer [60, 61]. Whereas tobacco 
consumption is the major risk factor of lung cancer in 
Europe and North America, exposure to air pollution from 
open fires used for cooking and heating within house-
holds is an additional cause of lung cancer in large parts 
of sub-Saharan Africa and in some regions of Asia and 
Info box 7:  Data from the German 
Centre for Cancer Reg- 
istry Data (ZfKD)
Data holder: German Centre for Cancer Reg-
istry Data at the Robert Koch Institute; epi-
demiological cancer registries of the German 
federal states
Aims: Aggregating data from the epidemio-
logical registries of the federal states in order 
to estimate the nationwide number of new 
cancer cases as well as prevalence and sur-
vival rates in Germany, stratified by cancer 
diagnosis, age and gender.
Registration method: Registration of all new 
cancer cases using electronic or paper 
reports filed by the doctors who diagnosed 
the case
Population: The population with residency 
in Germany (all age groups)
Coverage: Since 2009, complete nationwide 
coverage; the year in which registration 
began varies by state and ranges from 1970 
(Saarland) to 2009 (Baden-Württemberg). 
Currently, a registration completeness rate 
of 90-95% (nationwide) can be assumed for 
all types of cancer
Study period: Cases diagnosed between 
1 Jan 1998 and 31 Dec 2013 have been includ-
ed in the results presented here
Source: [28, 29]
More information in German is available at
www.krebsdaten.de
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years of age [77]. The authors discussed that in addition 
to changes in smoking habits, prenatal and early-child-
hood influences may be contributing to COPD morbid-
ity in later life [77]. Impaired growth and functional devel-
opment of the lungs also relates to COPD risk [50, 78, 
79]. In addition to a genetic predisposition and prenatal 
influences (e.g., maternal smoking during pregnancy), 
repeated respiratory infections in early childhood, expo-
sure to airborne pollutants, or childhood asthma may 
contribute to developing COPD in later adulthood [48, 
50, 68, 78-80]. Further work-related factors (such as expo-
sure to coal dust) are also important modifiable risk fac-
tors of COPD [48, 68, 81]. Moreover, exposure to high 
levels of air pollution in households that, for example, 
result from burning biomass (such as wood or animal 
dung) in open fires or leaky stoves is also a known cause 
of COPD [2, 3, 50, 82, 83]. This is particularly the case in 
low and middle income countries [3, 82, 83]. The survival 
prospects of people with COPD are further influenced 
by the quality of medical care, including prevention and 
treatment of concurrent conditions and sequelae (such 
as cardiovascular disease, but also respiratory infections 
and lung cancer) [50].
4.4 Asthma
Consistent with results observed at the global level, 
age-standardised asthma mortality rates and annual 
number of asthma deaths have both substantially 
decreased among women and men in Germany [51, 84]. 
The considerable faster decline in asthma mortality when 
compared with all-cause mortality indicates that sur- 
oping COPD depends on the total amount of cigarette 
smoking over time (‘pack years’) [2, 7]. However, reliable 
data on time trends in COPD morbidity or survival rates 
are not available in Germany [2, 48, 69]. Since a high pro-
portion of people with unknown or undiagnosed COPD 
within the population is to be expected, this would require 
a consideration of reliable data based on a pulmonary 
function test (spirometry) [70-73]. In the absence of such 
data, it cannot be determined to what extend differing 
time trends in COPD mortality between women and men 
can be attributed to gender differences in the develop-
ment of COPD incidence – e.g., due to secular trends in 
smoking – or survival rates and resulting changes in preva- 
lence (Info box 1) over time [74, 75]. In addition, COPD 
is a long-term chronic condition that may progress over 
decades accompanied by increasing health-related disa-
bility [2, 50]. Assessments of the burden of disease asso-
ciated with COPD therefore highly depend on the avail-
ability of reliable data permitting analyses on time trends 
in the number of years spent with health-related disabil-
ity [4, 5, 7]. In turn, this requires a reliable database for 
the analysis of trends in the prevalence of COPD and 
COPD-related disability over time [4, 5, 7].
In international comparison, such as with data from 
Hannover (2006), there is a regional association between 
the local average amount of cigarette smoking over the 
time (‘pack years’) and the prevalence of COPD [76]. In 
Spain, moreover, a decline in COPD prevalence esti-
mates based on spirometry testing was observed among 
adults aged 40 to 69 years between 1997 and 2007. This 
decline in prevalence was recorded across all age groups 
among men and in particular among women under 50 
Info box 8:  Data from the panel 
component of the Ger-
man Health Interview 
and Examination Survey 
for Adults (DEGS)
Data holder: Robert Koch Institute
Aims: Providing information on the inci-
dence and course of major diseases and 
associated risk factors between 1997-1999 
and 2008-2011
Methods: Paper-and-pencil self-adminis-
tered questionnaire, physical examinations 
and laboratory tests, a physician-adminis-
tered computer-assisted medical history tak-
ing, computer-assisted medication review
Population: People (aged 18 to 79 years at 
baseline) with permanent residency in Ger-
many
Sampling: Stratified two-stage sample in 
which adults from 120 municipalities in Ger-
many were randomly selected from popula-
tion registries
Participants: 7,124 adults (18-79 years) for the 
baseline survey; 3,959 adults (28-91 years) 
for the follow-up
Response rate: 61% at baseline;  
62% at follow-up
Study period: Baseline survey in 1997-1999 
(GNHIES98); follow-up survey in  
2008-2011 (DEGS1)
Source: [30-32]
More Information in German is available at
www.degs-studie.de
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view and examination surveys among adults (1997-1999 
and 2008-2011) as well as among children and adoles-
cents (2003-2006 and 2009-2012) [47, 49, 104]. At the 
same time, an increase in the 12-month prevalence was 
also observed, which, among adults, was attributable 
mainly to an increase in prevalence among women [49, 
105]. In addition to changes in asthma incidence, 
improved survival of asthma patients could have con-
tributed to the observed changes in prevalence. In large 
population-based epidemiological studies, data on 
asthma prevalence and incidence is based on self-re-
ported information and particularly relies on the assess-
ment of self-reported physician-diagnosed asthma [46, 
98, 106-111]. Thus, secular trends in degrees of asthma 
awareness or changes in the way patients perceive symp-
toms and seek medical care over time may all affect lev-
els of self-reported asthma prevalence and incidence [94, 
95, 106, 112].
4.5 Summary overview and conclusions
Both the burden of acute respiratory infections and the 
resulting need for medical care are subject to strong sea-
sonal fluctuations. A close (weekly) surveillance of short-
term trends in incidence is thus as relevant to health pol-
icy as the analysis of long-term trends over time. A large 
proportion of influenza-related deaths are attributed to 
existing chronic underlying diseases or to complications 
frequently associated with bacteria-related pneumonia 
instead of the acute influenza infections themselves. 
Therefore, evaluations of mortality using the official sta-
tistics on causes of death are inadequate and additional 
vival prospects of asthma patients may have improved. 
This development has been related particularly to 
improvements in drug therapy of asthma patients [51, 
84]. However, low asthma mortality rates could probably 
be reduced even further, particular through the imple-
mentation of appropriate medical care, including ade-
quate management of the condition by patients them-
selves [51, 85]. In the current analyses, the incidence rate 
of asthma during the observation period between 1997-
1999 and 2008-2011 among women was higher than 
among men. Results from other epidemiological studies 
also point to an increased asthma risk for women com-
pared to men, whereby this difference is already evident 
in adolescence, and besides hormonal factors, differ- 
ences in lung development or in the vulnerability (sus-
ceptibility) to environmental factors have been related 
to the observed gender differences in asthma incidence 
[42, 86-90]. Further, no nationwide studies are available 
on long-term trends in asthma incidence or survival rates 
in Germany [2, 91, 92]. 
Repeated population-based surveys have, however, 
demonstrated that the prevalence (Info box 1) of asthma 
increased during the second half of the last century not 
only in Germany, but also in other parts of the world [46, 
93-102]. This increase has been linked to changes in life-
style and environmental factors (such as infections, 
exposure to microbes, allergens and airborne pollutants, 
or diet) possibly resulting in an increment in asthma 
incidence particularly among children and young adults 
[46, 94-96, 99, 103]. Most recently, a further rise in the 
lifetime prevalence of physician-diagnosed asthma 
among both genders was recorded from national inter-
Info box 9:  Age-standardised  
incidence and  
mortality rates
Age standardisation: Age standardisation is used to 
compare measures of disease frequency or mortali-
ty rates (Info box 1 and 2) of populations with differ-
ent age structures. It is used when investigating 
trends within a geographically defined population to 
account for age structure changes over time. To cal-
culate an age standardisation, 'crude' incidence or 
mortality rates for individual age groups are deter-
mined and applied to a standard population with a 
fixed age distribution. In the current analyses of 
time trends in incidence and mortality rates, the 
‘old’ European standard population is used as the 
standard population. This statistical method ena-
bles analyses of incidence and mortality rates that 
are independent of changes and differences in age 
structure of the population.
 
Age-standardised incidence and mortality rates: This 
can be illustrated with the example of lung cancer 
among men (Figure 5 and 6). In 2013 in Germany, 
34,693 incident cases of lung cancer (ICD-10: 
C33-C34) were recorded within the framework of na-
tionwide cancer registration – more than the 32,589 
that were recorded fifteen years earlier in 1998. 
Does this mean that men now more frequently de-
velop lung cancer? This question can be examined 
using the age-standardised incidence rate: the 
age-standardised incidence rate for lung cancer in 
1998 was 73.4 per 100,000 population, whereas in 
2013 it was 58.6 – a substantially lower rate. When 
age-standardisation is employed to take the ageing 
population into account, it becomes clear that the 
rate of incident cases of lung cancer among men 
has in fact decreased considerably during the period 
in question.
Continued on next page
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[114, 115]. This is particularly the case among elderly 
patients with multiple chronic diseases, as they are sig-
nificantly more likely to suffer from a severe illness which 
could even have a fatal outcome [114].
The results of the present investigation illustrate a 
number of aspects that are of particular relevance for the 
continuous analysis of time trends in morbidity and mor-
tality of respiratory diseases. Detailed analyses of gender 
and age-specific trends enables conclusions to be drawn 
about changes in underlying behavioural or environmen-
tal determinants of disease that may explain these trends 
(for example, temporal changes in tobacco consumption 
and the incidence rates for lung cancer). At the same 
time, trends in morbidity and mortality for age-associ-
ated diseases such as COPD and lung cancer are also 
influenced by changes to the population age structure. 
This can be seen, for example, in the difference in time 
trends between the absolute number of incident cases 
and age-standardised incidence rates for lung cancer 
among men (Info box 9). Clearly, temporal changes in 
mortality rates can also be influenced by changes in sur-
vival, such as through improved treatments. Regarding 
lung cancer, survival rates are estimated regularly in Ger-
many as part of national cancer surveillance activities in 
accordance with the Federal Cancer Registry Data Act [24, 
116, 117]. For COPD and asthma, mortality follow-up of 
national health survey participants could help to close 
this gap in the future [74, 118, 119]. Additional informa-
tion can be derived by considering process data of in- and 
outpatient care [75, 120].
Based on data from the official statistics on causes 
of death, the present analysis investigated time trends 
assessments of the excess mortality associated with influ-
enza are necessary. For that purpose, the method of esti-
mating influenza-related excess mortality has been imple-
mented in Germany (Info box 10) [56]. However, compared 
to other countries, timely data that could provide an 
up-to-date assessment of time trends in the influenza-at-
tributable mortality in Germany are lacking [113].
Regarding chronic lung diseases including lung can-
cer, long-term trends in incidence and mortality rates are 
of particular relevance. A decline in asthma mortality 
rates is observed among both genders. However, mor-
tality rates for COPD and lung cancer are decreasing 
among men, whereas they are increasing among women. 
Incidence trends for longer periods of time are only avail-
able for lung cancer and remain at a very similar level to 
mortality rates. The contrasting developments in lung 
cancer incidence and mortality among women and men 
can be attributed to sex differences in smoking habits 
that occurred in the second half of the 20th century – the 
proportion of men who smoked was already declining 
during this time, whereas it was still increasing among 
women [58]. Overall, the proportion of smokers in Ger-
many has decreased in recent years, but still around one 
quarter of adults is currently smoking (women: 20.8%, 
men: 27.0%, see also fact sheet on Smoking among 
adults in Germany in issue 2/2017). The sustainable 
reduction of tobacco consumption is therefore an impor-
tant goal in terms of preventing lung cancer and COPD 
as well as other chronic diseases. In addition, some of 
the burden of disease and premature mortality associ-
ated with acute respiratory infections could be avoided 
by vaccination (influenza and pneumococcal vaccination) 
The average annual percentage change (AAPC) was 
-1.5%, which was statistically significant. Therefore, 
the rate of incident cases of lung cancer has actually 
decreased by 1.5% per year. The absolute number of 
incident cases rose because the number of people in 
older age groups increased. The observed time 
trends in the annual number of incident cases and 
age-standardised incidence rates for lung cancer 
among men were comparable to the corresponding 
time trends in the annual number of deaths and 
age-standardised mortality rates. Age standardisa-
tion enables evaluation of time trends in incidence 
and mortality rates, preventing an increasing number 
of older people within a given population from influ-
encing the results.
Source: [129]
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quality control in death registration and the implemen-
tation of multi-causal coding of the underlying diseases 
that led to the death represents a major challenge for 
the future [127, 128].
4.6 Conclusion
This article underlines the need for continuous and coor-
dinated surveillance of morbidity and mortality related 
to acute respiratory infections as well as lung cancer, 
COPD and asthma as chronic lung diseases of high pub-
lic health relevance. In doing so, it is essential that the 
association between respiratory diseases and the con-
currence of other, mainly age-related, diseases is taken 
into account. The analysis of existing data – also with 
regard to their limitations and the potential for future 
development – is a particularly important step in estab-
lishing sustainable surveillance structures in Germany 
within the framework of international public health strat-
egies aimed at the prevention and control of communi-
cable and non-communicable diseases.
in mortality of severe acute respiratory infections and 
chronic lung diseases, including lung cancer with a high 
relevance to public health. Compared to lung cancer, 
which represents a clearly defined underlying disease, 
there is a far higher risk of misclassification for COPD 
or asthma as the underlying cause of death, not least 
because of the possible overlap of both diseases in mid-
dle and older age [50, 121-123]. However, a decline in 
asthma mortality was evident also among younger peo-
ple aged 5 to 34 years. The fact that patients with COPD 
often suffer from other chronic diseases, such as cardio- 
vascular disease or lung cancer, can also affect the risk 
of death [123, 124]. Furthermore, it is particularly difficult 
to identify the single cause of death in COPD patients 
with severe acute respiratory infections [123, 124]. Besides, 
the analysis of time trends in mortality based on data 
from the official statistics on causes of death faces a lim-
itation due to the fact that coding practices can change 
over long periods of time. For example, since the death 
certificates are processed electronically in England and 
Spain using the IRIS software, dementia is now docu-
mented more frequently as an underlying cause of death 
instead of aspiration pneumonia (pneumonia due to 
substances entering the lungs, such as after swallowing 
food). In these cases, by contrast, manual coding would 
more likely have resulted in an acute respiratory illness 
being documented as the underlying cause of death [125, 
126]. In Germany, the electronic coding of causes of 
death using IRIS software has been piloted at the regional 
level since 2007; some federal states now use the sys-
tem to process all of their death certificates electronically 
[127]. Improving the statistics on causes of death through 
Info box 10:  Excess mortality 
of influenza [6] 
Influenza-related excess mortality: Excess mortality re-
fers to an increased rate of death among a particular 
population compared to the population’s average 
rate, or an increased number of deaths over a certain 
period of time compared to the normally expected 
death rate at that time of year. In order to calculate 
influenza-related excess mortality, the background 
mortality rate is usually calculated – this is the mor-
tality rate that would be expected during the respec-
tive period (month, week) if no influenza activity 
were present. If the level of mortality present during 
the influenza season is – to a greater or lesser extent 
– higher than the background level, this excess mor-
tality can be attributed to influenza [6]. 
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5. Annex
Annex Table 1 
Trends in age-standardised mortality rates 
(deaths per 100,000 population) due to respira-
tory diseases of high public health relevance 
and for all causes of death between 1998 
and 2015, Germany (old European standard 
population; ≥0 years of age) by gender and age 
Data source: Official statistics on 
causes of death [8]
ICD-10 codes Period APC (95% CI) Period APC (95% CI) AAPC (95% CI)
J09-J22 (Severe acute respiratory infections)
Women
0-54 years 1998-2015 -1.0 -2.5/0.5
55-74 years 1998-2015 -0.7 -1.6/0.2
≥75 years 1998-2005 2.0 -1.3/5.5 2005-2015 -4.9 -6.8/-3.1 -2.1 -3.7/-0.5
Men
0-54 years 1998-2015 -1.6 -2.4/-0.7
55-74 years 1998-2015 -1.2 -1.9/-0.4
≥75 years 1998-2005 0.8 -2.0/3.8 2005-2015 -3.7 -5.1/-2.2 -1.8 -3.2/-0.5
C33-C34 (Malignant neoplasms of the trachea, bronchus and lung)
Women
0-54 years 1998-2008 1.6 0.8/2.4 2008-2015 -2.8 -4.0/-1.6 -0.2 -0.8/0.4
55-74 years 1998-2003 2.7 1.4/4.0 2003-2015 3.9 3.6/4.2 3.6 3.2/3.9
≥75 years 1998-2015 1.6 1.5/1.8
Men
0-54 years 1998-2007 -2.6 -3.1/-2.0 2007-2015 -4.4 -5.2/-3.7 -3.5 -3.9/-3.0
55-74 years 1998-2007 -2.7 -3.0/-2.4 2007-2015 -0.8 -1.2/-0.4 -1.8 -2.1/-1.6
≥75 years 1998-2012 -1.0 -1.2/-0.7 2012-2015 -2.7 -5.1/-0.4 -1.3 -1.7/-0.9
J40-J44, J47 (COPD and other chronic lower respiratory diseases excluding asthma)
Women
0-54 years 1998-2015 1.5 0.6/2.5
55-74 years 1998-2006 0.0 -1.7/1.6 2006-2015 6.4 5.2/7.7 3.3 2.4/4.3
≥75 years 1998-2015 1.5 1.0/2.0
Men
0-54 years 1998-2015 -0.6 -1.3/0.1
55-74 years 1998-2008 -2.9 -4.1/-1.8 2008-2015 3.2 1.2/5.3 -0.4 -1.4/0.5
≥75 years 1998-2015 -1.4 -1.8/-1.0
ICD-10=10th revision of the International Statistical Classification of Diseases and Related Health Problems Continued on next page
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Annex Table 1 (continued) ICD-10 codes Period APC (95% CI) Period APC (95% CI) AAPC (95% CI)
J45-J46 (Asthma)
Women
0-54 years 1998-2015 -7.5 -8.2/-6.8
55-74 years 1998-2015 -9.6 -10.2/-8.9
≥75 years 1998-2007 -10.4 -11.7/-9.1 2007-2015 -4.2 -6.3/-1.9 -7.5 -8.6/-6.4
Men
0-54 years 1998-2008 -9.0 -10.7/-7.2 2008-2015 -2.7 -6.8/1.6 -6.4 -8.2/-4.6
55-74 years 1998-2008 -14.6 -15.6/-13.6 2008-2015 -8.1 -11.4/-4.6 -12.0 -13.3/-10.6
≥75 years 1998-2010 -14.1 -15.1/-13.1 2010-2015 -8.0 -14.1/-1.5 -12.3 -14.0/-10.6
A00-T98 (All causes of death)
Women
0-54 years 1998-2007 -2.5 -2.8/-2.2 2007-2015 -1.6 -2.0/-1.2 -2.1 -2.3/-1.8
55-74 years 1998-2007 -2.5 -2.8/-2.2 2007-2015 -0.2 -0.6/0.2 -1.4 -1.7/-1.2
≥75 years 1998-2015 -1.3 -1.5/-1.1
Men
0-54 years 1998-2003 -2.2 -2.8/-1.6 2003-2006 -3.8 -6.5/-1.1 -2.6 -3.0/2.1
2006-2015 -2.3 -2.6/-2.1
55-74 years 1998-2008 -2.9 -3.1/-2.6 2008-2015 -0.6 -1.1/-0.1 -1.9 -2.2/-1.7
≥75 years 1998-2008 -2.2 -2.7/-1.7 2008-2015 -0.4 -1.2/0.3 -1.5 -1.9/-1.1
APC=annual percentage change, and 95% confidence interval (95% CI)
AAPC=average annual percentage change, and 95% confidence interval (95% CI) between 1998 and 2015
COPD=chronic obstructive pulmonary disease
ICD-10=10th revision of the International Statistical Classification of Diseases and Related Health Problems
24
Journal of Health Monitoring Time trends in incidence and mortality of respiratory diseases of high public health relevance in Germany FOCUS
Journal of Health Monitoring 2017 2(3)
Annex Table 2 
Trends in age-standardised incidence rates 
(incident cases per 100,000 population) for 
malignant neoplasms of the trachea, bronchus 
and lung (ICD-10 C33-C34) between 1998 
and 2013, Germany (old European standard 
population; ≥0 years of age) by age and gender 
Data Source: German Centre for Cancer 
Registry Data [28, 29]
ICD-10 codes Period APC (95% CI) Period APC (95% CI) AAPC (95% CI)
C33-C34 (Malignant neoplasms of the trachea, bronchus and lung)
Women
0-54 years 1998-2000 9.9 1.0/19.6 2000-2007 2.4 1.1/3.6 1.8 0.7/3.0
2007-2013 -1.4 -2.5/-0.2
55-74 years 1998-2005 4.2 3.9/4.5 2005-2008 5.7 3.8/7.6 4.3 4.0/4.7
2008-2013 3.6 3.2/4.0
≥75 years 1998-2004 2.2 1.4/2.9 2004-2008 4.5 2.5/6.5 2.1 1.5/2.7
2008-2013 0.1 -0.7/0.9
Men
0-54 years 1998-2010 -2.0 -2.2/-1.8 2010-2013 -4.9 -6.4/-3.3 -2.6 -2.9/-2.3
55-74 years 1998-2000 -0.4 -2.9/2.2 2000-2005 -2.4 -3.2/-1.6 -1.3 -1.7/-0.9
2005-2013 -0.8 -1.1/-0.5
≥75 years 1998-2002 -2.3 -3.6/-1.0 2002-2011 -0.2 -0.6/0.2 -1.4 -2.0/-0.9
2011-2013 -5.2 -8.5/-1.9
APC=annual percentage change, and 95% confidence interval (95% CI)




per 1,000 PY (95% CI)
Incidence rate* 
per 1,000 PY (95% CI)
Women
Total (18-79 years) 4.1 (2.8-5.7) 3.4 (2.2-4.6) 2.7 (1.7-3.6)
18-44 years 3.6 (1.9-6.1) 3.0 (1.3-4.6) 1.8 (0.8-2.8)
45-79 years 4.7 (2.8-7.3) 4.0 (2.2-5.8) 3.7 (2.0-5.5)
Men
Total (18-79 years) 1.6 (0.9-2.6) 1.3 (0.7-2.0) 1.1 (0.5-1.7)
18-44 years 1.9 (1.0-3.5) 1.6 (0.7-2.6) 1.4 (0.5-2.3)
45-79 years 1.2 (0.5-2.2) 1.0 (0.3-1.6) 0.6 (0.2-1.0)




Annex Table 3 
Cumulative incidence and incidence rates 
(per 1,000 person-years, PY) for asthma 
among adults (18-79 years of age) 
Data source: German Health Interview and 
Examination Survey for Adults 1997-1999 
and 2008-2011 [30-32]
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Annex Figure 1 
Trends in age-standardised incidence rates 
(incident cases per 100,000 population) for 
malignant neoplasms of the bronchus and lung 
(ICD-10 C34) between 1998 and 2013, 
Germany (selected registries; old European 
standard population; ≥0 years of age) 
by gender and type of lung cancer
histology: 
In accordance with the current International 
Classification of Diseases for Oncology 
(ICD-O-3), the figures were divided into 
small-cell lung cancers (8041-8045), 
 adenocarcinomas (8140-8384), 
squamous cell carcinomas (8050-8080), 
 non-specific lung carcinomas (8000-8005), 
 and other malignant lung carcinomas 
(8010-8011) 
 Data Source: German Centre for Cancer 







Incident cases per 100,000 population




































































 squamous cell carcinomas
26
Journal of Health Monitoring Time trends in incidence and mortality of respiratory diseases of high public health relevance in Germany FOCUS
Journal of Health Monitoring 2017 2(3)
11. World Health Organization (WHO) (2014) Global status report 
on noncommunicable diseases 2014. WHO, Genf
12. World Health Organization (WHO) Global Influenza Programme 
(2015) A Manual for Estimating Disease Burden Associated With 
Seasonal Influenza. WHO, Genf
13. World Health Organization (WHO) (2013) Global Action Plan for 
the Prevention and Control of NCDs 2013-2020. WHO, Genf
14. Buda S, Prahm K, Preuß U et al. (2016) Bericht zur Epidemiolo-
gie der Influenza in Deutschland Saison 2015/16. RKI, Berlin
15. Hoffken G, Lorenz J, Kern W et al. (2009) Epidemiologie, Diag-
nostik, antimikrobielle Therapie und Management von erwachse-
nen Patienten mit ambulant erworbenen unteren Atemwegsinfek-
tionen sowie ambulant erworbener Pneumonie - Update 2009. 
S3-Leitlinie der Paul-Ehrlich-Gesellschaft für Chemotherapie, der 
Deutschen Gesellschaft für Pneumologie und Beatmungsmedi-
zin, der Deutschen Gesellschaft für Infektiologie und vom Kom-
petenznetzwerk CAPNETZ. Pneumologie 63(10):e1-68
16. Schnoor M, Hedicke J, Dalhoff K et al. (2007) Approaches to esti-
mate the population-based incidence of community acquired 
pneumonia. J Infect 55(3):233-239
17. Ewig S, Hoffken G, Kern WV et al. (2016) [Behandlung von 
erwachsenen Patienten mit ambulant erworbener Pneumonie 
und Prävention - Update 2016. Pneumologie 70(3):151-200
18. Cassini A, Plachouras D, Eckmanns T et al. (2016) Burden of Six 
Healthcare-Associated Infections on European Population 
Health: Estimating Incidence-Based Disability-Adjusted Life Years 
through a Population Prevalence-Based Modelling Study. PLoS 
Med 13(10):e1002150
19. Zentralinstitut für die kassenärztliche Versorgung (Zi) (2016) Die 
50 häufigsten ICD-10-Schlüsselnummern nach Fachgruppe aus 
dem ADT-Panel des Zentralinstituts Jahr 2015.  
https://www.zi.de/cms/fileadmin/images/content/PDFs_alle/
Die_50_häufigsten_ICD-2015.pdf (As at 03.08.2017)
20. Albrecht M (2015) Regionale Unterschiede von Krankenhaushäu-
figkeiten bei ambulant-sensitiven Konditionen. Vortrag beim 14. 





pdf (As at 03.08.2017)
21. Pollmanns J, Romano PS, Weyermann M et al. (2017) Impact of 
Disease Prevalence Adjustment on Hospitalization Rates for 
References
1. World Health Organization (WHO) (2007) Global surveillance, 
prevention and control of chronic respiratory diseases: a compre-
hensive approach. J. Bousquet, N. Khaltaev (eds) WHO, Genf
2. Gillissen A, Welte T (eds) (2014) Weißbuch Lunge 2014 – Her-
ausforderungen, Zukunftsperspektiven, Forschungsansätze – Zur 
Lage und Zukunft der Pneumologie in Deutschland. Frisch Texte 
Verlag, Herne
3. Ferkol T, Schraufnagel D (2014) The global burden of respiratory 
disease. Ann Am Thorac Soc 11(3):404-406
4. Global Burden of Disease 2015 Disease and Injury Incidence and 
Prevalence Collaborators (2016) Global, regional, and national 
incidence, prevalence, and years lived with disability for 310 dis-
eases and injuries, 1990-2015: a systematic analysis for the Glob-
al Burden of Disease Study 2015. Lancet 388(10053):1545-1602
5. Global Burden of Disease 2015 DALYs and HALE Collaborators 
(2016) Global, regional, and national disability-adjusted life-years 
(DALYs) for 315 diseases and injuries and healthy life expectancy 
(HALE), 1990-2015: a systematic analysis for the Global Burden 
of Disease Study 2015. Lancet 388(10053):1603-1658
6. Global Burden of Disease 2015 Mortality and Causes of Death 
Collaborators (2016) Global, regional, and national life expectan-
cy, all-cause mortality, and cause-specific mortality for 249 caus-
es of death, 1980-2015: a systematic analysis for the Global Bur-
den of Disease Study 2015. Lancet 388(10053):1459-1544
7. Plass D, Vos T, Hornberg C et al. (2014) Entwicklung der Krank-
heitslast in Deutschland. Ergebnisse, Potenziale und Grenzen 
der Global Burden of Disease Study. Dtsch Arztebl Int 
111(38):629-638
8. Statistisches Bundesamt (2017) Sterbefälle, Sterbeziffern (je 
100.000 Einwohner, altersstandardisiert) (ab 1998). Gliederungs-
merkmale: Jahre, Region, Alter, Geschlecht, Nationalität, ICD-10, 
Art der Standardisierung.  
www.gbe-bund.de (As at 03.08.2017)
9. Kassenärztliche Bundesvereinigung (2016) Die häufigsten Krank-
heiten in deutschen Arztpraxen.  
http://www.kbv.de/media/sp/Infografik_KBV_Krankheiten.jpg 
(As at 03.08.2017)
10. Marschall J, Hildebrandt S, Sydow S et al. (2017) Gesundheitsre-
port 2017. Beiträge zur Gesundheitsökonomie und Versorgungs-
forschung (Band 16). medhochzwei Verlag, Heidelberg
27
Journal of Health Monitoring Time trends in incidence and mortality of respiratory diseases of high public health relevance in Germany FOCUS
Journal of Health Monitoring 2017 2(3)
32. Scheidt-Nave C, Kamtsiuris P, Gößwald A et al. (2012) German 
health interview and examination survey for adults (DEGS) - 
design, objectives and implementation of the first data collection 
wave. BMC Public Health 12:730
33. Kurth BM, Lange C, Kamtsiuris P et al. (2009) Gesundheitsmoni-
toring am Robert Koch-Institut. Sachstand und Perspektiven. 
Bundesgesundheitsblatt Gesundheitsforschung Gesundheits-
schutz 52(5):557-570
34. Buda S, Tolksdorf K, Schuler E et al. (2017) Establishing an ICD-
10 code based SARI-surveillance in Germany - description of the 
system and first results from five recent influenza seasons. BMC 
Public Health 17(1):612
35. Lopez-Campos JL, Ruiz-Ramos M, Soriano JB (2014) Mortality 
trends in chronic obstructive pulmonary disease in Europe, 1994-
2010: a joinpoint regression analysis. Lancet Respir Med 2(1):54-62
36. Adair T, Hoy D, Dettrick Z et al. (2012) 100 years of mortality due 
to chronic obstructive pulmonary disease in Australia: the role of 
tobacco consumption. Int J Tuberc Lung Dis 16(12):1699-1705
37. Burney PG, Patel J, Newson R et al. (2015) Global and regional 
trends in COPD mortality, 1990-2010. Eur Respir J 45(5):1239-1247
38. Li L, Shen C, Li X et al. (2013) On weighting approaches for miss-
ing data. Stat Methods Med Res 22(1):14-30
39. Upham JW, James AL (2011) Remission of asthma: The next ther-
apeutic frontier? Pharmacol Ther 130(1):38-45
40. Aaron SD, Vandemheen KL, FitzGerald JM et al. (2017) Reevalua-
tion of Diagnosis in Adults With Physician-Diagnosed Asthma. 
JAMA 317(3):269-279
41. Basagana X, Sunyer J, Zock JP et al. (2001) Incidence of asthma 
and its determinants among adults in Spain. Am J Respir Crit 
Care Med 164(7):1133-1137
42. Eagan TM, Brogger JC, Eide GE et al. (2005) The incidence of 
adult asthma: a review. Int J Tuberc Lung Dis 9(6):603-612
43. National Cancer Institute (2015) Software „Joinpoint Regression 
Programm“, Version 4.4.0.0.
44. Kim HJ, Fay MP, Feuer EJ et al. (2000) Permutation tests for join-
point regression with applications to cancer rates. Stat Med 
19(3):335-351
45. Burney P, Jarvis D, Perez-Padilla R (2015) The global burden of 
chronic respiratory disease in adults. Int J Tuberc Lung Dis 
19(1):10-20.
Chronic Ambulatory Care-Sensitive Conditions in Germany. 
Health Serv Res. Doi: 10.1111/1475-6773.12680
22. Freund T, Heller G, Szecsenyi J (2014) [Hospitalisations for 
ambulatory care sensitive conditions in Germany]. Z Evid Fort-
bild Qual Gesundhwes 108(5-6):251-257
23. Statistisches Bundesamt (2017) Diagnosedaten der Krankenhäu-
ser ab 2000 (Fälle/Sterbefälle, Fälle je 100.000 Einwohner 
(altersstandardisiert), Berechnungs- und Belegungstage, durch-
schnittliche Verweildauer) (ab 2000). Gliederungsmerkmale: Jah-
re, Wohnsitz, Alter, Geschlecht, Verweildauer, ICD10-3-Steller, Art 
der Standardisierung.  
http://www.gbe-bund.de (As at 03.08.2017)
24. Robert Koch-Institut (eds) (2016) Bericht zum Krebsgeschehen 
in Deutschland 2016. RKI, Berlin
25. Robert Koch-Institut, Statistisches Bundesamt. Das Informati-
onssystem der Gesundheitsberichterstattung des Bundes  
www.gbe-bund.de (As at 03.08.2017)
26. Kopke K, Prahm K, Buda S et al. (2016) Evaluation einer ICD-10-ba-
sierten elektronischen Surveillance akuter respiratorischer Erkran-
kungen (SEEDARE) in Deutschland. Bundesgesundheitsblatt 
Gesundheitsforschung Gesundheitsschutz 59(11):1484-1491
27. Uphoff H, Stalleicken I, Bartelds A et al. (2004) Are influenza sur-
veillance data useful for mapping presentations? Virus Res 103(1-
2):35-46
28. Robert Koch-Institut (2017) Zentrum für Krebsregisterdaten. 
Datenabfrage.  
www.krebsdaten.de (As at 03.08.2017) 
29. Wolf U, Barnes B, Bertz J et al. (2011) Das Zentrum für Krebsre-
gisterdaten (ZfKD) im Robert Koch-Institut. Bundesgesundheits-
blatt Gesundheitsforschung Gesundheitsschutz 54(11):1229-1234
30. Gößwald A, Lange M, Kamtsiuris P et al. (2012) DEGS: Studie 
zur Gesundheit Erwachsener in Deutschland. Bundesweite Quer- 
und Längsschnittstudie im Rahmen des Gesundheitsmonito-
rings des Robert Koch-Instituts. Bundesgesundheitsblatt 
Gesundheitsforschung Gesundheitsschutz 55(6-7):775-780
31. Kamtsiuris P, Lange M, Hoffmann R et al. (2013) Die erste Welle 
der Studie zur Gesundheit Erwachsener in Deutschland (DEGS1): 
Stichprobendesign, Response, Gewichtung und Respräsentativi-
tät. Bundesgesundheitsblatt Gesundheitsforschung Gesund-
heitsschutz 56(5-6):620-630 
http://edoc.rki.de/oa/articles/reOjvEr900Q1Q/PDF/22VmD-
7JrO6CNg.pdf (As at 03.08.2017)
28
Journal of Health Monitoring Time trends in incidence and mortality of respiratory diseases of high public health relevance in Germany FOCUS
Journal of Health Monitoring 2017 2(3)
56. Zucs P, Buchholz U, Haas W et al. (2005) Influenza associated 
excess mortality in Germany, 1985-2001. Emerg Themes Epidemi-
ol 2:6
57. Buchholz U (2015) Aktualisierung der der Influenza zugeschrie-
benen Mortalität, bis einschließlich der Saison 2012/2013. Epide-
miologisches Bulletin (03):17-20
58. Kuntz B, Zeiher J, Lampert T (2016) Tabak – Zahlen und Fakten 
zum Konsum. In: Deutsche Hauptstelle für Suchtfragen e.V. 
(eds) Jahrbuch Sucht 2016. Pabst, Lengerich, S. 55-87
59. Eikmann T, Dopp E, Herr C (2010) Die Wirkung von Fein- und 
Feinststäuben auf die menschliche Gesundheit. In: Gemein-
schafts-Arbeitsausschuss »Feinstäube« der Gesellschaft Deut-
scher Chemiker e.V. (GDCh), Gesellschaft für Chemische Technik 
und Biotechnologie e.V. (DECHEMA), Kommission Reinhaltung 
der Luft (KRdL) im VDI und DIN-Normenausschuss, ProcessNet 
(eds) Statuspapier Feinstaub DECHEMA e.V., Frankfurt am Main, 
P. 153-170
60. Böckelmann I (2014) Die ESCAPE-Studie. Prospektive Analysen 
zur Assoziation der Feinstaubexposition mit Lungenkrebs. Der 
Pneumologe 11(3):252-254
61. Valavanidis A, Vlachogianni T, Fiotakis K et al. (2013) Pulmonary 
oxidative stress, inflammation and cancer: respirable particulate 
matter, fibrous dusts and ozone as major causes of lung carcino-
genesis through reactive oxygen species mechanisms. Int J Envi-
ron Res Public Health 10(9):3886-3907
62. Lim SS, Vos T, Flaxman AD et al. (2012) A comparative risk 
assessment of burden of disease and injury attributable to 67 
risk factors and risk factor clusters in 21 regions, 1990-2010: a 
systematic analysis for the Global Burden of Disease Study 2010. 
Lancet 380(9859):2224-2260
63. Devesa SS, Bray F, Vizcaino AP et al. (2005) International lung can-
cer trends by histologic type: male:female differences diminishing 
and adenocarcinoma rates rising. Int J Cancer 117(2):294-299
64. Lewis DR, Check DP, Caporaso NE et al. (2014) US lung cancer 
trends by histologic type. Cancer 120(18):2883-2892
65. Pesch B, Kendzia B, Gustavsson P et al. (2012) Cigarette smok-
ing and lung cancer – relative risk estimates for the major histo-
logical types from a pooled analysis of case-control studies. Int J 
Cancer 131(5):1210-1219
66. Samet JM, Avila-Tang E, Boffetta P et al. (2009) Lung cancer in 
never smokers: clinical epidemiology and environmental risk fac-
tors. Clin Cancer Res 15(18):5626-5645
46. Jarvis D (2014) Asthma and rhinitis. In: Annesi-Maesano I, Lund-
bäck B, Viegi G et al. (eds) Respiratory epidemiology. European 
Respiratory Society, Sheffield
47. Langen U, Schmitz R, Steppuhn H (2013) Häufigkeit allergischer 
Erkrankungen in Deutschland. Ergebnisse der Studie zur 
Gesundheit Erwachsener in Deutschland (DEGS1). Bundesge-
sundheitsblatt Gesundheitsforschung Gesundheitsschutz 56 
(5-6):698-706 
http://edoc.rki.de/oa/articles/reSp8JYqnpVo/PDF/20xkoi9E-
0FU4w.pdf (As at 03.08.2017)
48. Lundbäck B, Bakke P, Ingebrigtsen T et al. (2014) Chronic 
obstructive pulmonary disease. In: Annesi-Maesano I, Lundbäck 
B, Viegi G et al. (eds) Respiratory epidemiology. European Res-
piratory Society, Sheffield
49. Schmitz R, Thamm M, Ellert U et al. (2014) Verbreitung häufiger 
Allergien bei Kindern und Jugendlichen in Deutschland. Ergebnis-




Ms.pdf (As at 03.08.2017)
50. Global Initiative for Chronic Obstructive Lung Disease (2017) 
Global Strategy for the Diagnosis, Management and Prevention 
of COPD.  
http://goldcopd.org/gold-2017-global-strategy-diagnosis-man-
agement-prevention-copd/ (As at 27.07.2017)
51. The Global Asthma Network (2014) The Global Asthma Report 
2014. Auckland, New Zealand
52. World Health Organisation (WHO) (2014) Global Epidemiologi-
cal Surveillance Standards for Influenza. WHO, Genf
53. Institut für Qualitätssicherung und Transparenz im Gesundheits-
wesen (IQTiG) (2016) Bundesauswertung zum Erfassungsjahr 




(As at 03.08.2017) 
54. An der Heiden M, Buchholz U (2017) Estimation of influenza-at-
tributable medically attended acute respiratory illness by influen-
za type/subtype and age, Germany, 2001/02-2014/15. Influenza 
Other Respir Viruses 11(2):110-121
55. McCullers JA (2014) The co-pathogenesis of influenza viruses 
with bacteria in the lung. Nat Rev Microbiol 12(4):252-262
29
Journal of Health Monitoring Time trends in incidence and mortality of respiratory diseases of high public health relevance in Germany FOCUS
Journal of Health Monitoring 2017 2(3)
79. Martinez FD (2016) Early-Life Origins of Chronic Obstructive Pul-
monary Disease. N Engl J Med 375(9):871-878
80. Gauderman WJ, Urman R, Avol E et al. (2015) Association of 
improved air quality with lung development in children. N Engl J 
Med 372(10):905-913
81. Baur X (2011) Obstruktive Atemwegserkrankungen als Berufs-
krankheiten. Pneumologie 65(11):654-661
82. GBD 2015 Risk Factors Collaborators (2016) Global, regional, and 
national comparative risk assessment of 79 behavioural, environ-
mental and occupational, and metabolic risks or clusters of risks, 
1990-2015: a systematic analysis for the Global Burden of Dis-
ease Study 2015. Lancet 388(10053):1659-1724
83. World health Organisation (WHO) (2016) Household air pollu-
tion and health. Fact sheet N°292. Updated February 2016. 
http://www.who.int/mediacentre/factsheets/fs292/en/  
(As at 03.08.2017)
84. Burney P (2013) Death and disability due to asthma. In: Akdis CA, 
Agache I (eds) Global Atlas of Asthma. European Academy of 
Allergy and Clinical Immunology, Zürich, P. 14-17
85. Levy ML (2014) National Review of Asthma Deaths (NRAD). Br J 
Gen Pract 64(628):564
86. Zemp E, Hansen S, Schneider C et al. (2014) Sex, gender and res-
piratory health. In: Annesi-Maesano I, Lundbäck B, Viegi G et al. 
(eds) Respiratory epidemiology. European Respiratory Society, 
Sheffield
87. Zein JG, Erzurum SC (2015) Asthma is Different in Women. Curr 
Allergy Asthma Rep 15(6):28
88. Fuchs O, Bahmer T, Rabe KF et al. (2017) Asthma transition from 
childhood into adulthood. Lancet Respir Med 5(3):224-234
89. Winer RA, Qin X, Harrington T et al. (2012) Asthma incidence 
among children and adults: findings from the Behavioral Risk 
Factor Surveillance system asthma call-back survey – United 
States, 2006-2008. J Asthma 49(1):16-22
90. Vink NM, Postma DS, Schouten JP et al. (2010) Gender differences 
in asthma development and remission during transition through 
puberty: the TRacking Adolescents' Individual Lives Survey 
(TRAILS) study. J Allergy Clin Immunol 126(3):498-504 e491-496
91. Aumann I, Prenzler A, Welte T et al. (2014) Epidemiologie und 
Kosten von Asthma bronchiale in Deutschland - eine systemati-
sche Literaturrecherche. Pneumologie 68(8):557-567
67. Umweltbundesamt (2017) Entwicklung der Luftqualität.  
http://www.umweltbundesamt.de/themen/luft/daten-karten/ent-
wicklung-der-luftqualitaet#textpart-1 (As at 03.08.2017)
68. European Respiratory Society (2013) Major respiratory diseases - 
chronic obstructive pulmonary disease. In: Gibson J, Lodden-
kemper R, Sibille Y et al. (eds) The European Lung White Book - 
Respiratory Health and Disease in Europe. European Respiratory 
Society, Sheffield
69. Aumann I, Prenzler A (2013) Epidemiologie und Kosten der 
COPD in Deutschland - Eine Literaturrecherche zu Prävalenz, 
Inzidenz und Krankheitskosten. Klinikarzt 42(4):168-172
70. Karrasch S, Bruske I, Smith MP et al. (2016) What is the impact 
of different spirometric criteria on the prevalence of spirometri-
cally defined COPD and its comorbidities? Results from the pop-
ulation-based KORA study. Int J Chron Obstruct Pulmon Dis 
11:1881-1894
71. Lamprecht B, Soriano JB, Studnicka M et al. (2015) Determinants 
of underdiagnosis of COPD in national and international surveys. 
Chest 148(4):971-985
72. Geldmacher H, Biller H, Herbst A et al. (2008) Die Prävalenz der 
chronisch obstruktiven Lungenerkrankung (COPD) in Deutsch-
land. Ergebnisse der BOLD-Studie. Dtsch Med Wochenschr 
133(50):2609-2614
73. Colak Y, Afzal S, Nordestgaard BG et al. (2017) Prognosis of 
asymptomatic and symptomatic, undiagnosed COPD in the gen-
eral population in Denmark: a prospective cohort study. Lancet 
Respir Med 5(5):426-434
74. Ford ES, Mannino DM, Zhao G et al. (2012) Changes in mortality 
among US adults with COPD in two national cohorts recruited 
from 1971-1975 and 1988-1994. Chest 141(1):101-110
75. Doucet M, Rochette L, Hamel D (2016) Incidence, Prevalence, 
and Mortality Trends in Chronic Obstructive Pulmonary Disease 
over 2001 to 2011: A Public Health Point of View of the Burden. 
Can Respir J 2016:7518287
76. Burney P, Jithoo A, Kato B et al. (2014) Chronic obstructive pul-
monary disease mortality and prevalence: the associations with 
smoking and poverty--a BOLD analysis. Thorax 69(5):465-473
77. Soriano JB, Ancochea J, Miravitlles M et al. (2010) Recent trends 
in COPD prevalence in Spain: a repeated cross-sectional survey 
1997-2007. Eur Respir J 36(4):758-765
78. Lange P, Celli B, Agusti A et al. (2015) Lung-Function Trajectories 
Leading to Chronic Obstructive Pulmonary Disease. N Engl J 
Med 373(2):111-122
30
Journal of Health Monitoring Time trends in incidence and mortality of respiratory diseases of high public health relevance in Germany FOCUS
Journal of Health Monitoring 2017 2(3)
104. Schlaud M, Atzpodien K, Thierfelder W (2007) Allergische 
Erkrankungen. Ergebnisse aus dem Kinder- und Jugendgesund-
heitssurvey (KiGGS). Bundesgesundheitsblatt Gesundheitsfor-
schung Gesundheitsschutz 50(5-6):701-710 
http://edoc.rki.de/oa/articles/reRhnrND9xOGA/PDF/27Kp0kRU-
qJI.pdf (As at 03.08.2017)
105. Schmitz R (2015) Trends in der Prävalenz von Asthma bronchiale 
und allergischer Rhinitis bei Erwachsenen in Deutschland 1997-
99 und 2008-11. Fortbildungsveranstaltung für den Öffentlichen 
Gesundheitsdienst. Berlin.  
http://www.bfr.bund.de/cm/343/trends-in-der-praevalenz-von-as-
thma-bronchiale-und-allergischer-rhinitis.pdf (As at 01.03.2017)
106. Bjerg A, Ekerljung L, Middelveld R et al. (2011) Increased preva-
lence of symptoms of rhinitis but not of asthma between 1990 
and 2008 in Swedish adults: comparisons of the ECRHS and 
GA(2)LEN surveys. PLoS One 6(2):e16082
107. de Marco R, Cappa V, Accordini S et al. (2012) Trends in the preva- 
lence of asthma and allergic rhinitis in Italy between 1991 and 
2010. Eur Respir J 39(4):883-892
108. Jarvis D, Newson R, Lotvall J et al. (2012) Asthma in adults and 
its association with chronic rhinosinusitis: the GA2LEN survey in 
Europe. Allergy 67(1):91-98
109. Kainu A, Pallasaho P, Piirila P et al. (2013) Increase in prevalence 
of physician-diagnosed asthma in Helsinki during the Finnish 
Asthma Programme: improved recognition of asthma in primary 
care? A cross-sectional cohort study. Prim Care Respir J 22(1):64-71
110. Kilpelainen M, Terho EO, Helenius H et al. (2001) Validation of a 
new questionnaire on asthma, allergic rhinitis, and conjunctivitis 
in young adults. Allergy 56(5):377-384
111. Sembajwe G, Cifuentes M, Tak SW et al. (2010) National income, 
self-reported wheezing and asthma diagnosis from the World 
Health Survey. Eur Respir J 35(2):279-286
112. Ellsasser G, Diepgen TL (2002) Atopische Erkrankungen und 
soziale Lage bei Einschulungskindern im Land Brandenburg. 
Bundesgesundheitsblatt Gesundheitsforschung Gesundheits-
schutz 45(3):267-276
113. Vestergaard LS, Nielsen J, Krause TG et al. (2017) Excess all-
cause and influenza-attributable mortality in Europe, December 
2016 to February 2017. Euro Surveill 22(14):30506 
114. Remschmidt C, Harder T, Wichmann O et al. (2016) Hinter-
grundpapier der STIKO: Evaluation der bestehenden Influen-
zaimpfempfehlung fur Indikationsgruppen und fur Senioren 
92. Genuneit J, Grabenhenrich L, Kämer U et al. (2012) Epidemiolo-
gische Forschung zu allergischen Erkrankungen in Deutschland: 
eine Chronologie. Allergologie 35(1):3-10
93. Anandan C, Nurmatov U, van Schayck OC et al. (2010) Is the 
prevalence of asthma declining? Systematic review of epidemio-
logical studies. Allergy 65(2):152-167
94. Eder W, Ege MJ, von Mutius E (2006) The asthma epidemic. N 
Engl J Med 355(21):2226-2235
95. Kramer U, Schmitz R, Ring J et al. (2015) What can reunification 
of East and West Germany tell us about the cause of the allergy 
epidemic? Clin Exp Allergy 45(1):94-107
96. Sunyer J, Anto JM, Tobias A et al. (1999) Generational increase of 
self-reported first attack of asthma in fifteen industrialized coun-
tries. European Community Respiratory Health Study (ECRHS). 
Eur Respir J 14(4):885-891
97. Landesamt für Verbraucherschutz Sachsen-Anhalt (2014) Auswir-
kungen der Umwelt auf die Gesundheit von Kindern. Schulanfän-
gerstudie 1991-2014. Landesamt für Verbraucherschutz Sach-
sen-Anhalt, Magdeburg
98. Bergmann KC, Heinrich J, Niemann H (2016) Current status of 
allergy prevalence in Germany: Position paper of the Environ-
mental Medicine Commission of the Robert Koch Institute. Aller-
go J Int 25:6-10
99. Kramer U, Link E, Oppermann H et al. (2002) Die Schulanfänger-
studie in West- und Ostdeutschland (SAWO): Trends von Allergi-
en und Sensibilisierungen 1991-2000. Gesundheitswesen 
64(12):657-663
100. Heinrich J, Hoelscher B, Frye C et al. (2002) Trends in prevalence 
of atopic diseases and allergic sensitization in children in Eastern 
Germany. Eur Respir J 19(6):1040-1046
101. Krämer U, Möllemann A, Behrendt J (2001) Epidemiologie aller-
gischer Erkrankungen bei Kindern. Bundesgesundheitsblatt 
Gesundheitsforschung Gesundheitsschutz 44:633–642
102. Maziak W, Behrens T, Brasky TM et al. (2003) Are asthma and 
allergies in children and adolescents increasing? Results from 
ISAAC phase I and phase III surveys in Munster, Germany. Aller-
gy 58(7):572-579
103. Yunginger JW, Reed CE, O'Connell EJ et al. (1992) A communi-
ty-based study of the epidemiology of asthma. Incidence rates, 
1964-1983. Am Rev Respir Dis 146(4):888-894
31
Journal of Health Monitoring Time trends in incidence and mortality of respiratory diseases of high public health relevance in Germany FOCUS
Journal of Health Monitoring 2017 2(3)
126. Wells C (2014) Impact of the Implementation of IRIS Software for 
ICD-10 Cause of Death Coding on Mortality Statistics, England and 
Wales. Statistical bulletin. Office for National Statistics, London 
127. Eckert O (2015) MUSE - ein neuer Baustein der elektronischen 
Todesursachenstatistik. Methoden – Verfahren – Entwicklungen. 
Nachrichten aus dem Statistischen Bundesamt (01):08-10
128. Prognos AG (2013) Studie Aufwand-Nutzen-Abschätzung zum 





ters.pdf (As at 03.08.2017)
129. Robert Koch-Institut (2015) Gesundheit in Deutschland. Kapitel 2. 
Wie steht es um unsere Gesundheit? Gesundheitsberichterstat-
tung des Bundes. Gemeinsam getragen von RKI und Destatis. 
RKI, Berlin 
http://edoc.rki.de/documents/rki_fv/refNzCggQ8fNw/
PDF/29PIbXnI56Jfc.pdf (As at 03.08.2017)
(Standardimpfung ab 60 Jahren). Bundesgesundheitsblatt 
Gesundheitsforschung Gesundheitsschutz 59(12):1606-1622
115. Falkenhorst G, Remschmidt C, Harder T et al. (2016) Background 
paper to the updated pneumococcal vaccination recommenda-
tion for older adults in Germany. Bundesgesundheitsblatt 
Gesundheitsforschung Gesundheitsschutz 59(12):1623-1657
116. Kraywinkel K, Barnes B, Dahm S et al. (2014) Von regionalen 
Daten zu bundesweiten Aussagen. Die Methoden im Zentrum 
für Krebsregisterdaten. Bundesgesundheitsblatt Gesundheitsfor-
schung Gesundheitsschutz 57(1):13-21
117. Robert Koch-Institut, Gesellschaft der epidemiologischen Krebs-
register in Deutschland e.V., (eds) (2015) Krebs in Deutschland 
2011/2012. 10. Ausgabe. RKI, Berlin
118. Cheng YJ, Gregg EW, Rolka DB et al. (2016) Using multi-year 
national survey cohorts for period estimates: an application of 
weighted discrete Poisson regression for assessing annual 
national mortality in US adults with and without diabetes, 2000-
2006. Popul Health Metr 14:48
119. Paprott R, Schaffrath Rosario A, Busch MA et al. (2015) Associa-
tion between hemoglobin A1c and all-cause mortality: results of 
the mortality follow-up of the German National Health Interview 
and Examination Survey 1998. Diabetes Care 38(2):249-256
120. Afonso AS, Verhamme KM, Sturkenboom MC et al. (2011) COPD 
in the general population: prevalence, incidence and survival. 
Respir Med 105(12):1872-1884
121. Jensen HH, Godtfredsen NS, Lange P et al. (2006) Potential mis-
classification of causes of death from COPD. Eur Respir J 
28(4):781-785
122. Bopp M, Spoerri A, Zwahlen M et al. (2009) Cohort Profile: the 
Swiss National Cohort--a longitudinal study of 6.8 million people. 
Int J Epidemiol 38(2):379-384
123. McGarvey LP, John M, Anderson JA et al. (2007) Ascertainment 
of cause-specific mortality in COPD: operations of the TORCH 
Clinical Endpoint Committee. Thorax 62(5):411-415
124. McGarvey LP, Magder S, Burkhart D et al. (2012) Cause-specific 
mortality adjudication in the UPLIFT(R) COPD trial: findings and 
recommendations. Respir Med 106(4):515-521
125. Floristan Floristan Y, Delfrade Osinaga J, Carrillo Prieto J et al. 
(2016) Coding Causes of Death with IRIS Software. Impact in 
Navarre Mortality Statistic. Rev Esp Salud Publica 90:e1-9
32
Journal of Health Monitoring Time trends in incidence and mortality of respiratory diseases of high public health relevance in Germany FOCUS
Journal of Health Monitoring 2017 2(3)
Imprint
The Robert Koch Institute is a Federal Institute within  
the portfolio of the German Federal Ministry of Health
This work is licensed under a 
Creative Commons Attribution 4.0 
International License.
Journal of Health Monitoring
Author details
Robert Koch Institute









The authors declared no conflicts of interest. 
Funding
The DEGS study was funded by the Robert Koch Institute and the 
German Federal Ministry of Health.
Note  







Susanne Bartig, Johanna Gutsche, Dr Franziska Prütz,  
Martina Rabenberg, Alexander Rommel, Dr Anke-Christine Saß, 
Stefanie Seeling, Martin Thißen, Dr Thomas Ziese
Robert Koch Institute
Department of Epidemiology and Health Monitoring
General-Pape-Str. 62–66
D-12101 Berlin




Gisela Dugnus, Alexander Krönke, Kerstin Möllerke
Translation
Simon Phillips/Tim Jack
Please cite this publication as 
Steppuhn H, Buda S, Wienecke A et al. (2017) Time trends in 
incidence and mortality of respiratory diseases of high public health 
relevance in Germany. Journal of Health Monitoring 2(3):3–33  
DOI 10.17886/RKI-GBE-2017-061
ISSN 2511-2708
33
